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When your determination changes,  
everything will begin to move in the direction you desire.  
The moment you resolve to be victorious, every nerve and fiber  
in your being will immediately orient itself toward your success. 
 On the other hand, if you think, “This is never going to work out,”  
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List of Abbreviation 
3D Three dimensional  
ADME Absorption Distribution Metabolism 
Excretion ALI Air-Liquid Interface 
AM Alveolar Macrophages 
AO Adverse Outcome 
AOP Adverse Outcome Pathway 
ASL Air Surface Liquid 
AT-I Alveolar Type I Cells 
AT-II Alveolar Type II Cells 
BEAS-2B Bronchial Epithelial Cell Line 
BCRP Breast cancer resistance protein 
BCA kit Bicinchoninic Acid Assay protein 
determination kit CaCl2 Calcium Chloride  
cAMP Adenosine 3,5-Cyclic Monophosphate 
Ca2+ Calcium Ions 
CBF Cilia Beating Frequency 
CCH Carbachol 
CdCl2 Cadmium Chloride 
CF Cystic fibrosis 
CFTR Cystic fibrosis transmembrane conductance 
regulator CFTR Cystic fibrosis transmembrane conductance 
Inhibitor-172 
cGMP Guanosine 3,5-cyclic monophosphate 
COPD Chronic obstructive pulmonary disease 
CYP450 Cytochrome P450 
cldn Claudin 
DMSO Dimethyl sulfoxide 
DPI dry-powder inhaler 
EMA European Agency for the Evaluation of 
Medicinal Products ENaC Epithelial sodium channels 
EPDExS Electrostatic Particulate Dosage and Exposure 
System ER Efflux Ratio 
EXTN Eotaxin 
FDA Food and Drug Administration 
FMO Flavin-Containing Monooxygenases 
FRSK Forskolin 
GAM- plate Goat Anti Mouse plate 
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GRO Growth-regulated oncogene chemokines 
HBSS Hank’s Balanced Salt Solution 
HBSSH Hank’s Balanced Salt Solution with HEPES 
HPLC-MS/MS high performance liquid chromatography 
coupled with mass spectrometry analysis 
HPLC-UV high performance liquid chromatography 
coupled with ultra violet analysis   
IATA Integrated Approaches to Testing and 




MIP-1β Macrophage inflammatory protein-1β 
ICRP International Commission on Radiological 
Protection 
IP-10 Interferon gamma-induced protein 10 
IS Integrated Strategy 
ITS Integrated Testing Strategy 
LDH Lactate Dehydrogenase 
LY yellow luciferase marker 
LPS Lipopolysaccharide  
LC-MS/MS liquid chromatography coupled with mass 
spectrometry analysis L/min Liter per minute 
MAO Monoamine Oxidase 
Mg2+ Magnesium Ions 
MCC Muco-ciliary Clearance 
MIE Molecular Initiating Event 
MIP-1β Macrophage inflammatory protein 1β 
MOA Mode of Action 
MRP Multidrug resistance-related protein 
MSD-based assay Meso Scale Discovery’s Assay 
MPPD multiple-path particle dosimetry model 
NACIVT Nano Aerosol Chamber for In Vitro Toxicity 
NAD+ Nicotinamide adenine dinucleotide oxidized  
NADH Nicotinamide adenine dinucleotide reduced  
NCEs New Chemical Entities 
NCRP National Council on Radiation Protection and 
Measurements 
NGI Next Generation Impactor 
OAT Organic anion transporters 
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OATP Organic anion transporting polypeptides 
OCT Organic cation transporters 
OCTN Organic cation/carnitine transporters 
OECD Organisation for Economic Co-operation and 
Development Papp apparent p rmeability 
p-SMAD2 Phospho- Small Mothers Against 
Decapentaplegic PEPT Oligopeptide transporters 
PNECs Pulmonary neuroendocrine cells 
P-gp P-glycoprotein 
PK Pharmacokinetic 
QSAR Quantitative Structure Activity Relationship 
RFU relative fluorescence unit 
RANTES Regulated upon Activation, Normal T cell 
Expressed, and Secreted RPMI Roswell Park Memorial Institute 1640 
Medium SAECs Small Airway Epithelial Cells 
SLC Solute carrier 
SMAD Small Mothers Against Decapentaplegic 
SD standard deviation 
SMGs Submucosal glands 
TBST Tris Buffer Saline with Tween 20 
TB Clearance tracheal-bronco clearance 
TEER Trans-epithelial electrical resistance 
TGF-β Transforming growth factor beta 
tSMAD2 Total SMAD2 








Drug Inhalation is one of the most effective administration routes; in fact, first 
pass metabolism is bypassed, rapid action onset is enabled and drug doses can be 
kept relatively low compared to other administration routes.  
The most recent 3D in vitro models allow to mimic some of the pulmonary tissue 
functionalities. These models reproduce the air-liquid interface, with beating cilia 
and mucus production, since different types of cells are present. Therefore, these 
models could be possibly applied to multi-disciplinary investigations following 
liquid, dry powder or aerosol treatment.  
In this thesis, an integrated strategy is proposed, with the aim to increase the rate of 
success in the drug candidate selection phase. Ideally, safety data should be 
integrated with early pharmacokinetics (PK) and efficacy indications in order to 
increase chances to select the candidate with the highest safety margins. With this 
ambitious objective in mind, a human-based 3D model were evaluated as model for 
the toxicity assessment and drug permeability evaluation; some examples of the 
initial work previously conducted by other authors under the supervision of myself 
and other colleagues will be discussed (Pomari, 2019; Sembeni, 2020).  
In particular, a commercially available 3D respiratory model SmallAir™ has been 
qualified for: a) sensibility and specificity in the evaluation of lung toxicity 
potential of new compounds; b) permeability to test drug transport through tissues 
for formulation screening purposes; c) quantitative cytokine secretion on cell 
supernatant; d) cilia beating and muco-ciliary clearance evaluation by image 
analysis. 
These tests performed on a human tissue could provide more reliable results also 
because all tests were performed in the same model and this could be helpful in data 
integration. This approach could allow to fill gaps in drug discovery for human-
relevant screening of new chemical entities (NCEs), best formulation selection, 
including physiochemical equivalence evaluation generic drug development. In 
vitro and in silico data can be helpful in predicting PK and toxicity profiles prior to 
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preclinical and clinical studies. This allows to respect the 3Rs principle of 
replacement, reduction and refinement of in vivo studies. The proposed integrated 
testing strategy (ITS) has the potential to reduce the attrition in drug development, 
to optimize the inhaled formulation, to screen compounds for candidate selection 
and to reduce in vivo studies. 
For the toxicity tests, well-known respiratory toxic compound were tested both in 
the SmallAir™ model and in the A549 cell line model. On the basis of results, the 
SmallAir™ model seemed to be less sensitive than A549, probably due to the 3D 
structure physiological features. Cilia beating and mucus production can indeed 
protect the cells from the toxic effect miming the in vivo response.   
For the permeability study, well-known inhalation compounds with very different 
permeability values were evaluated both in SmallAir™ model and in the standard 
Caco2 cell model. For low and high permeable compounds results obtained were 
comparable in the two test considered systems. The most evident difference was 
observed with medium permeable compounds, suggesting that the SmallAir™ 
model should express different efflux pumps on their surface form the standard 
Caco2 cell model.   
The SmallAir™ model was also evaluated as in vitro model for the inflammatory 
mediators assessment. The treatment with TGF-β allowed to confirm the activation 
of the signalling via Smad2 while, inconclusive results were obtained with regards 
to cytokines and ROS release following Bleomycin treatment. 
The SmallAir™ model was finally evaluated as in vitro model for the assessment 
of the Muco-ciliary Clearance (MCC). Results obtained in this project, showed that 
the SmallAir™ can be a promising model to assess the MCC in vitro after treatment 
with compound acting on ATP release and Cystic fibrosis transmembrane 
conductance Inhibitor-172 (CFTR172inh).  
More test considering different compound, study design and end points has to be 
conducted, in order to identify a human relevant in vitro lung model to be applied 
in many fields of analysis.    
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2 INTRODUCTION AND BACKGROUND 
Respiratory drug delivery has raised a very strong interest within the 
pharmaceutical field. Inhalation therapy has been primarily applied for the 
treatment of respiratory diseases. Inhalation therapies are extensively used in 
asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis 
therapies. For local effects, inhaled drugs are delivered directly to the site of action 
in the lung, providing fast onset of action (within 5 minutes) (Hou et al., 2015). The 
lung has been used as an administration route for systemic delivery of anesthetics 
and many other therapeutic and recreational drugs (Gonda, 2000). Different reasons 
lead to an increased interest in the respiratory administration route, including the 
emergence of biotherapeutics that have delivery issues (i.e. their large molecular 
size, hydrophilicity and lability make difficult their formulation in traditional oral 
dosage forms such as tablets and capsules) (Agu et al., 2001) and a better 
understanding of the absorption properties of the lungs. Great exposure surface, 
high permeability, relatively low metabolic capacity and a rich blood supply make 
the lungs a suitable alternative non-invasive route for systemic drug administration 
(Chan et al., 2014; Forbes et al., 2011). Small molecules can be rapidly adsorbed 
from the lungs, with high bioavailability. Fast drug delivery is particularly effective 
to relieve acute symptoms such as pain, migraine and nausea (Farr & Otulana, 2006; 
Patton & Byron, 2007). For example, in January 2006, the Food and Drug 
Administration (FDA) and the European Agency for the Evaluation of Medicinal 
Products (EMA) approved the first inhaled therapeutic macromolecule for systemic 
delivery, the human insulin (Exubera™), to treat patients with type 1 and type 2 
diabetes (Lenzer et al., 2006). 
The advances in aerosol and formulation technology, as well as inhaler device 
technology, now allow to deliver therapeutic molecules to defined lung regions 
(Anderson et al., 2005). Commercial manufacturing processes are now in place for 
the production of delivery systems to overcome issues such as high costs and 
therapeutic limitations of biologics. The inhalation route has been evaluated also 
for low molecular weight drugs, previously administered by injection, for a faster 





Drug discovery to reach the candidate selection is challenging, time consuming and 
an expensive process. Also, the drug development process is articulated through 
several stages to assess safety, efficacy, and regulatory compliance (Error! 
eference source not found.). 
 
 
Figure 1. Steps of a generic drug discovery process. A considerable number of compounds 
discovered in the early phase are screened by appropriate screening models to select the 
potential candidate drug (Lead Optimization) for possible progression into drug 
development. The screening process consists of the integration of data obtained with in 
silico, in vitro and in vivo models (taken from A. Tronde, 2002)  
 
The first step in developing a new drug is the target identification and validation. 
Thousands of compounds may be potential candidates for the development of a new 
drug. However, after early testing on a specific target (Hit to Lead phase), only a 
small number of compounds show to be promising and can proceed for further 
studies. At this stage, the aim is to maintain the desired properties of lead 
compounds while improving on possible deficiencies of their structures, with a 
view to produce a preclinical drug candidate (Lead Optimisation phase). For this 
process, an integrated approach is recommended. The combination of specialists in 
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computational chemistry, medical chemistry, drug pharmacokinetic and 
metabolism, and other research areas can provide unique insights into this late stage 
of the process (Hughes et al., 2011). Once a compound has proved to be with the 
desired characteristics, usually described by Target Product Profile, it can be 
progressed to a development phase. The package of studies in the development 
phase consists of Absorption/Distribution/Metabolism/Excretion (ADME) studies, 
physico-chemical characterisation, formulation feasibility studies, toxicity and 
mutagenicity, dose selection and route of administration. Only if the compound 
passes all the preclinical test, it is then moved to the first in human clinical trial. 
The evaluation of all these properties of the new compound requires in silico, in 
vitro and in vivo studies.  
A large amount of drug discovery programs fails in bringing novel compounds to 
the market. In particular, unacceptable toxicity in the respiratory tract represents a 
major issue in the development of inhaled therapies and it has been reported to 
account for approximately 30% of inhaled project failure (Cook et al., 2014). 
Usually, respiratory toxicities have been identified at a relatively late stage in 
preclinical testing (Sivars et al., 2018). Therefore, an early assessment and 
prediction of toxicity potential can reduce late stage attrition with an impact on the 
number of animals used.  
 
2.1 The 3Rs principles and integrated approaches to testing and assessment 
(IATA) 
Since drug development is a long and costly process, in order to avoid wasting time, 
resources and animals, it is desirable to screen out drug candidates that are not 
suitable for development as potential medicines. Within the drug discovery and 
development process, laboratory animals’ use occurs in a step-wise manner. 
Pharmacokinetics and pharmacodynamic properties are assessed first, then 
followed by efficacy studies, before proceeding into candidate selection and 
regulatory safety testing. 
The different stages of the drug development are regulated by the International 
Conference on Harmonization (ICH) guidelines (e.g., ICH M3(R2)). The aim of 
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these guidelines is to harmonize the regulatory studies for medicines between the 
European Union, Japan and the Unites States. Respiratory drug development entails 
the standard preclinical toxicology tests, including genotoxicity studies and 
carcinogenic potential evaluation. In addition to safety assessment studies, in vivo 
pharmacokinetics studies in animals provide data on the outcome of a drug and its 
metabolites in the body by measurement of the drug concentrations in plasma or 
tissues. The information obtained during the early characterization of toxic effect is 
used to estimate an initial safe starting dose and dose range for the human clinical 
trials. These data together with the toxicological data, are needed for the regulatory 
submission, prior to starting Phase I clinical trials.  
The preclinical studies for the inhalation toxicity evaluation are technologically 
challenging and expensive. In fact, to expose animals to drugs by inhalation, special 
equipment, facilities, specific knowledge and skills are needed. Furthermore, the 
administration via inhalation route requires amounts of test compound larger than 
that for other routes of administration due to the continuous fresh aerosol deliver 
and the significant compound waste in the inhalation device.   
The conduction of in vivo studies is highly regulated. Directive 2010/63/EU (which 
revise the Directive 86/609/EEC on the protection of animals used for scientific 
purposes) was adopted on 22nd September 2010. This Directive is firmly based on 
the principle of the 3Rs, to replace, reduce and refine the use of animals used for 
scientific purposes, in all aspects of the development, manufacture and testing of 
medicines.  
The adoption of the 3Rs principle not only has an impact on animals, but in some 
cases, also offer scientific and business benefits by reducing costs and improving 
efficiency.  
Both in vivo and in vitro models have advantages and disadvantages. The term 
“model” implies an approximation of the human patho-physiology. The cell 
cultures technologies are the basis of the so-called “alternative” methods. The 
critical question about the in vitro models is how well the cells in culture can mimic 
the cell behaviours in the organism; similarly, the extent of human relevance needs 
to be considered also for laboratory animals on a case-by-case basis.  
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Up to now, models holistic enough to recapitulate the complexity of a tissue or 
organ as stand-alone are extremely rare, therefore, an integration of different 
approaches is currently considered as the way forward; in toxicology, this approach 
is called Integrated Testing Strategies (ITS) (Hartung et al., 2013).    
Extrapolation of animal data to predict a human outcome presents numerous 
challenges due to physiological, anatomical, and metabolic differences across 
species.  
Both scientific and ethical considerations have conducted to significant interest and 
investment in developing and using reliable human-relevant approaches without the 
use of animal to assess the toxicity of inhaled substances.  
A workshop on “Alternative Approaches for Acute Inhalation Toxicity Testing to 
Address Global Regulatory and Non-Regulatory Data Requirements” (Clippinger, 
Allen, Jarabek, et al., 2018) considered current testing requirements and the 
usefulness of using integrated approaches that combine existing data with in vitro 
and/or computational approaches.  
The integration of existing information, the physico-chemical properties of the 
substances, the expected human exposure, and data from in vitro and in silico 
models implemented in the inhaled drug development could help in optimizing the 
research approach with an impact on 3Rs principle. Furthermore, tiered testing can 
help in an early identification of highly toxic substances using assays that have 
higher throughput and are less expensive than in vivo studies, followed by more in-
depth testing of the remaining substances with more sophisticated in vitro methods. 
The report “Toxicity Testing in the 21st Century: A Vision and Strategy” suggests 
to transform toxicity testing from a system based on studies in laboratory animals 
to one established primarily on in vitro methods that evaluate changes in normal 
cellular signalling pathways using human-relevant cells or tissues (Krewski et al., 
2010). 
Transition to these more predictive approaches requires the production and 
acquisition of mechanistic data to better characterize biological systems in 
formalized descriptions. Considerable progress is being made in the explanation of 
cellular-response networks and connections between pathways consisting of 
complex interactions of genes, proteins, and small molecules that maintain normal 
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cellular function and are involved in the cellular response to compound treatment 
(Krewski et al., 2010). Cellular response pathways that, given a perturbation, are 
expected to lead to adverse health effects are termed toxicity pathways. 
This concept of pathway-based approaches in risk assessment has further evolved 
in the concept of ‘Adverse Outcome Pathways’ (AOPs). An AOP is a conceptual 
framework that describes a logical sequential chain of causally linked events at 
different levels of biological organisation, which follows exposure to a chemical 
and leads to an adverse health effect (Allen et al., 2014).  
Conceptually, an AOP can be considered as a series of essential, measurable events 
starting with the initial interaction of a stressor with a molecule in a target cell or 
tissue (i.e., the molecular initiating event, MIE), progressing through an inter-
connected series of key events at different levels of biological organization (cell, 
tissue, organ), leading to the manifestation of a toxic event (adverse outcome, AO) 
in single individuals or in populations (Error! Reference source not found.). 
OPs showed as a linear series of key events, in fact they constitute interdependent 
networks of events with feedback loops in which disease outcomes are initiated or 
modified (Bal-Price & Meek, 2017).  
 
Figure 2.  An AOP consists of key events (KEs) and key events relationships (KERs) starting from 
an initial interaction of a chemical with the biological system (molecular initiating event; 
MIE) through a sequence of KEs  leading to an adverse outcome (AO) of regulatory 




In 2012, the OECD launched a Development Program 
(http://www.oecd.org/chemicalsafety/testing/adverse-outcome-pathways-
molecular-screening-and-toxicogenomics.htm) with the subsequent release of a 
guideline for the description of AOPs (OECD, 2013) and a Handbook (OECD, 
2016), which describes best practices for defining, documenting and assessing 
AOPs in an associated AOP knowledge base (AOP-KB), based on background 
experience. The AOP approach is conceptually similar to that of mode of action 
(MOA) defined as a “biologically plausible series of key events leading to an 
adverse effect”.  
Well characterized AOPs may therefore provide a helpful support in data evaluation 
and integration in targeted and efficient testing strategies, commonly defined as 
integrated approaches to testing and assessment (IATA) (Worth & Blaauboer, 
2018). 
IATA are structured approaches that integrate and weight different types of data for 
the purposes of hazard identification and characterization and/or risk assessment of 
a chemical (Tollefsen et al., 2014). Based on the phase a IATA is intended for 
(compound screening and prioritization, risk assessment etc), its composition might 
be different. In fact, different data requirements, nature of tests (e.g. in vitro, in 
chemico, in vivo), use of possible non-testing methods (e.g., QSAR, read-across), 
data integration approaches and acceptable level of uncertainty considerations will 
drive the IATA. 
 
2.2 Respiratory tract anatomy and physiology 
The structure of the mammalian lung is optimized to fulfill its main function of gas 
exchanging.It is a complex organ and its function as a gas exchanger is directly 
determined by its microstructure (Weibel, 2017).  
The respiratory tract in humans and animals is a complex structure that can be 
divided into two functional regions: the conducting airway and the respiratory 
region. The conducting airways consists of: nasal cavity, nasopharynx, larynx, 
trachea, bronchi and bronchioles. In these regions the air is transported to/from the 
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lung, filtered, warmed and humidified. The respiratory unit is composed by the 
lungs with their millions of alveoli and capillaries where the gas exchanging occurs. 
From trachea to the periphery of the airway tree, the airways repeatedly branch 
dichotomously into two daughter branches with smaller diameters and shorter 
length than the parent branch (Weibel, 2017).The whole pulmonary tree is lined by 
a continuous layer of epithelial cells. The distribution of the epithelial cell types 
differs significantly, not only between species, but also within the various airway 
regions of each species (Error! Reference source not found.) (Bustamante-Marin 
 Ostrowski, 2017). 
 
Figure 3. A. Structure of the airways; B. The trachea and most proximally airways are lined by a 
pseudostratified epithelium formed by ciliated and secretory cells. (C) The small airways 
are lined by a simple cuboidal epithelium with fewer goblet cells. (D) The alveolar region 
is made of type I and type II alveolar cells (taken from Bustamante-Marin X.M., 2017). 
 
Air enters the respiratory system through the nose and mouth, travelling to the 
pharynx and the larynx which opens into the trachea. From the trachea, the air 
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passes to the bronchi, where branches into the right and left bronchi. Inside the 
lungs, the bronchi branches into smaller bronchioles until they reach the alveoli. 
The air-blood barrier of the gas exchange area is composed of the alveolar epithelial 
cells (surface area 140 m2) on one side and the capillary bed (surface area 130 m2) 
on the other side of a thin basement membrane (Tronde, 2002).  
The pulmonary epithelium is important for maintaining the normal functions of the 
respiratory system. As one of the primary interfaces between the organism and the 
environment, the respiratory system is constantly exposed to airborne particles, 
potential pathogens, and toxic gases in the inspired air (Plopper, 1996). Therefore, 
different defense mechanisms are involved, comprising mechanical (i.e. air 
filtration and muco-ciliar clearance), chemical and immunological defense 
mechanisms (Tronde, 2002).  
 
Epithelium 
The airway consists of more than 40 different cell types and the thickness of 
epithelial cell layer also varies within different airway regions along with the 
presence of different cell types (Upadhyay & Palmberg, 2018).  
In general, the epithelial cells of the proximal airway can be divided into the surface 
epithelial cells of the tracheal and bronchial regions and the cells of the submucosal 
glands. 
The epithelium at the level of tracheobronchial tract is composed of ciliated cells, 
non-ciliated secretory cells, and basal cells. Pulmonary neuroendocrine cells 
(PNECs) are present both as single cells and in clusters throughout the proximal 
airway. Submucosal glands (SMGs), characterized by a variable proportion of 
ciliated cells, mucous cells and serous cells (Chang et al., 2008) is a unique structure 
of the proximal cartilaginous airway. 
 
Ciliated cells constitute the main element in the conducting airway epithelium. They 
are covered with cilia and are roughly columnar in shape, with little variations in 
morphological appearance between species. The ciliated cells are attached to the 
basal lamina via desmosomes. In humans, the cilia are 0.25 m in diameter and 
range from 6 m in length in the proximal airway to 3.6 m in seventh generation 
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airway. Each cilium is anchored to the cell cytoplasm by a basal body through an 
axoneme (Chang et al., 2008). On their apical surface, the cilia remove inhaled 
particles trapped in the mucus creating a mucociliary flow. 
The ciliated cells are involved in the restoration and regeneration of bronchiolar 
epithelium after injury (Park et al., 2006). 
 
Basal Cells. The basal cells form a monolayer along the basement membrane and 
are responsible for the pseudostratified appearance of the epithelium. Basal cells 
are connected to the basement membrane through hemidesmosomes and provide 
the base for the attachment of ciliated and non-ciliated columnar cells to the basal 
lamina. The distribution of basal cells in airway epithelium is different in various 
airway tracts and in different animal species. Airways larger in diameter have a 
taller epithelium and more basal cells than airways smaller in diameter with a 
shorter epithelium. 
The first role of the basal cells is to repopulate all the major cell types acting as a 
stem cell (Hong et al., 2004). Furthermore, evidence indicates that basal cells are 
involved in regulating physiologic and inflammatory responses of the airway. In 
response to various inhaled agents, axons in the airway epithelium release 
neuropeptides into the lateral intercellular space, initiating the process of 
neurogenic inflammation (increased vascular permeability, neutrophil adhesion, 
vasodilatation, gland secretion; ion transport; smooth muscle contraction; increased 
cholinergic transmission; cough) (Van Winkle & Fanucchi, 2009). 
 
Non-ciliated secretory cells: The distribution of non-ciliated secretory cells in 
tracheobronchial epithelial cell types differs a lot among the species. In humans, 
ciliated cells predominate and are interspersed with mucus-secreting (goblet) cells 
(with approximately five ciliated cells for every goblet cell) (Chang et al., 2008). In 
rats, the most present  secretory cell is the serous cell, whereas in rabbits and mice, 
the Clara cell is the only type of secretory cell in the entire conducting airway 
(Plopper et al., 1983).   
 
 The Goblet cells are the principal secretory cells situated in the epithelium 
of the conducting airways, with their apical surfaces protruding into the 
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lumen. They are intercalated among ciliated cells and connected to adjacent 
cells by tight junctions; together these cells form a selective barrier lining 
along the respiratory tract. The morphology of goblet cells is highly 
polarized, with the nucleus and other organelles localized at the base of the 
cell. Under healthy conditions, goblet cells, together with submucosal 
glands, secrete high molecular weight mucous glycoproteins that allow t to 
properly capture and remove particles, and therefore to protect the epithelial 
surface. Once trapped, the particles are removed from the airways by the 
ciliated cells, by a process named muco-ciliary clearance (Alvarado & Arce, 
2016; Rogers et al., 1993). 
 
 Another secretory type of cell are the Clara cells (Club cells or non-ciliated 
bronchiolar secretory cells), which are predominantly present in the 
terminal and respiratory bronchioles epithelium of mammals including man, 
and in the upper airways of some species such as mice. Their primary 
function is to secrete the lung surfactants and other specific proteins that 
contribute to the ASL (Air Surface Liquid), to serve as progenitor cells for 
ciliated and secretory epithelial cells and to metabolize xenobiotic 
compounds. Indeed, Clara cells are able to metabolize xenobiotics through 
their cytochrome p450 monooxygenase activity, a function that makes them 
susceptible to injury by lipophilic compounds (Baron et al., 1988). 
 The predominant secretory cells in rat surface epithelium are the Surface 
Serous Cells (Rogers et al., 1993). They morphologically resemble the 
serous cell type of the submucosal gland, and they have been identified in 
the human for the first time by Rogers AV et al. in 1993. 
 
In the alveolar region, four cell types are present: the epithelial type I and II cells, 
alveolar brush cells (type III) and alveolar macrophages (Plopper, 1996).  
 Alveolar type I cells (AT-I). The AT-I are large and flat squamous cells. 
They comprise 95% of the alveolar epithelium and their relatively simple 
structure allows them to act as a thin, gas-permeable membranes (Rozycki, 
2014). These cells are also involved in the maintenance of ion and fluid 
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balance. The AT-1 contains a number of ion transport channels, including 
the amiloride-sensitive epithelial sodium channels (ENaC), Cystic fibrosis 
transmembrane conductance regulator chloride channels (CFTR), and a 
variety of potassium channels, which help to maintain the electrochemical 
gradient needed for ion movement (Hollenhorst et al., 2011). 
 Alveolar type II cells (AT-II). The AT-II cells, which cover 3–5% of the 
alveolar surface area, are cuboidal epithelial cells and have been labelled 
defenders of the alveolus for their immunomodulatory functions. The AT-
II cells can produce cytokines and chemokines, such as TNF-α, IL-6, IL-1β, 
monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory 
protein 1α (MIP-1α), growth related oncogene α (GRO-α) and granulocyte-
macrophage colony stimulating factor (GM-CSF) in response to various 
forms of lung injury induced by bacteria, viruses, or mechanical ventilation. 
AT-II cells also produce, secrete, and recycle surfactants, which can 
enhance chemotaxis, bacterial uptake and phagocytosis by alveolar 
macrophages, but can also inhibit cytokine production in response to LPS 
(Wong & Johnson, 2013). 
 Alveolar macrophages. The alveolar macrophages are a type of white blood 
cells and take part in the cellular components of the immune system, they 
are the first response to invading respiratory pathogens. They originate from 
monocytes in the blood and evolve in the lungs. Since inhaled drug particles 
may be recognized as pathogens, these cells play an important role in the 
drug’s pharmacokinetic. Furthermore, alveolar macrophages are capable of 
producing a wide range of pro- and anti-inflammatory cytokines. They are 
cleared from the alveoli to the bronchioles by the lining fluid, and then from 
the airways by the muco-ciliary escalator (Sibille & Reynolds, 1990; 
Stanke, 2015).  
 
The Airway Surface Liquid 
The airways are lined with an Airway Surface Liquid (ASL) film in two layers. 
Around the cilia is the aqueous layer (sol phase); over this, a viscous mucus layer 
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(gel phase) can be found. The low viscosity of the sol phase allows the cilia to beat, 
while the gel phase traps inhaled particles. The ASL has a crucial role in protecting 
the airways and alveoli from any potentially inhaled particles. The mucus comes 
predominantly from the mucus gland and goblet cells in the surface epithelium 
(Widdicombe, 2002). 
The major macromolecular constituents of the mucous layer are the mucin 
glycoproteins. The mucin proteins are encoded by MUC genes, and many of them 
are expressed in the airways, including the gel-forming mucins MUC5AC, 
MUC5B, MUC2, MUC8, and MUC19. In healthy airways, the goblet cells typically 
express MUC5AC, whereas mucosal cells of the submucosal glands express 
primarily MUC5B (Groneberg et al., 2002). The secretion of mucin can be 
stimulated by many factors, including paracrine and autocrine mediators, especially 
ATP. Increased production and secretion of mucins is a feature of many chronic 
airway diseases, including asthma, Chronic Obstructive Pulmonary Disease 
(COPD), and cystic fibrosis (CF) (Rose & Voynow, 2006). 
Water transport across epithelia is secondary to active trans-epithelial transport of 
solutes, which creates local concentration gradients across the epithelium and 
results in water movement by osmosis. 
The regulation of the relative rates of Na versus Cl ions transport occurs in the 
apical domain of the airway epithelial cell. The relevant ion channels, e.g. epithelial 
Na channel and CFTR, and most of their intracellular regulators, are localized 
within the apical plasma membrane (P. Huang et al., 2001). 
 
The surfactants 
Between these two layers of ASL, there are the surfactants. Lung surfactants have 
a complex composition of unique phospholipids and proteins secreted by Clara cells 
and AT-II cells. 
Their specific function is to reduce the surface tension at the pulmonary air-liquid 
interface. 
About 80% of surfactants are glyceropholipids, with a minor contributions of 
sphingomyelin. Roughly 10% of mammalian surfactant is cholesterol. The 
phospholipids composition assure function under dynamic changes of the air–liquid 
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interface area during respiration. A 2-5% of surfactant is composed by surfactant 
proteins (SP-a, -B, -C and –D) (Bernhard, 2016). The two hydrophilic proteins SP-
A and SP-D are calcium-dependent lectins and are important for primary defense 
mechanism of the lung as well as in alveolar surfactant homeostasis (Haagsman & 
Diemel, 2001). The two hydrophobic surfactant proteins SP-B and SP-C are 
essential to optimize alveolar surfactant function. The presence of surfactants in the 
alveolar fluid can promote the solubility of drugs, and consequently the dissolution 
of poorly water-soluble drugs. Furthermore, the pulmonary surfactants have good 
capabilities in spreading, facilitating transport and preventing adhesion of inhaled 
particles (Velaga et al., 2018). 
 
2.3 In vivo models for inhaled compounds studies 
For the purposes of assessing toxic end points and ADME/PK of inhaled 
compounds, animal-based studies have limitations in a variety of aspects. These 
include not only ethical considerations relating to animal experiments, but also, and 
above all, their biological relevance; their high costs and technical complexity need 
to be also considered. Airways in rodent and in human are anatomically very 
different. These variations modify air flow rates and air speed in the airways which 
affect the deposition the clearance and the retention of inhaled agents (Clippinger, 
Allen, Jarabek, et al., 2018).  
There are evident differences in the anatomy and geometry of airways. Rodents 
have less extensive airway branching than humans. In the mouse, there are six to 
eight generations of intra-pulmonary branches with a stereotypical branching 
pattern. While in humans, there are more generations of intrapulmonary branches, 
with cartilage plates and smooth muscle surrounding the intrapulmonary airways at 
the the lung level (Clippinger, Allen, Jarabek, et al., 2018; Matute-Bello et al., 
2011). The trachea of a mouse has an internal diameter of approximately 1.5 mm as 
opposed to the average human trachea that has an internal diameter of 
approximately 12 mm (Lacroix et al., 2018). Also, the cells type composition differs 
between non clinical species and humans (Clippinger, Allen, Jarabek, et al., 2018). 
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The breathing mode is one of the most obvious and significant physiological 
differences between rodents and humans. Humans are oronasal breathers while 
rodents breathe mandatory via nose. . This difference causes a less adequate 
filtration of particles and gases in the humans due to oral breathing compared to 
nasal breathing, with a consequent  greater delivery of material to the peripheral 
airways (Clippinger, Allen, Jarabek, et al., 2018).  
Other aspects that differ among species are the chemotactic attraction of 
macrophages implicated in clearance and biochemical mechanisms of airway 
activation and detoxification (Bogdanffy & Keller, 1999; Csanády et al., 1993).  
An essential requirement for a non-animal method is the relevance and 
comparability with the anatomical characteristics that it should represent being 
modeled. Based on  these considerations, animal models can only reproduce some 
aspects of complex human diseases such as lung fibrosis, emphysema (Moore & 
Hogaboam, 2008) and COPD (Wright et al., 2008). Because of significant 
differences in lung physiology they are not able to recapitulate the full spectrum of 
human patho-physiology and this can explain why over 80% of drugs that pass 
preclinical phases in rodents fail to demonstrate efficacy in patients during clinical 
trials (Miller & Spence, 2017). 
The ideal model would enable to reproduce not only the different phenotypic 
lesions such as emphysema, small airway remodeling (including goblet cell 
metaplasia), chronic bronchitis, and pulmonary hypertension, but also the 
molecular mechanisms leading to them in humans. For example, several different 
approaches have been used in the effort to represent COPD in animals, but there are 
some more general principles that will affect any COPD model such as considerable 
differences among species in lung development and maturation; in lung anatomy 
and responsiveness to toxic agents (Wright et al., 2008). 
2.4 In vitro cell-models 
Cell-based models are crucial in the drug discovery and development process. To 
be suitable for in vitro studies (toxicology studies, permeability evaluation and 
compound efficacy assessment) the cell culture models should simulate the 
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functions and the defense mechanism of the lung epithelium in the best possible 
manner. 
Well-known in vitro models are being routinely used to assess the air pollution-
mediated respiratory toxicity and lung diseases to enhance knowledge on molecular 
and pathophysiological mechanisms. For example, if a compound is known to be 
metabolized (or if it is unknown if the compound is subjected to a toxification or 
detoxification mediated by the metabolism), an in vitro cell culture model must be 
metabolically competent. Similarly, if the transport of a compound has to be 
evaluated, the model should express the physiological barrier functionalities and 
transporters. 
Many pulmonary models have been developed with several level of complexity. In 
vitro cell culture can be set up by using primary cultures or continuously growing 
cell lines. The in vitro lung models extend from simple cell-free biochemical assays, 
to submerged monoculture models to the most new and sophisticated multi-cell type 
cultures grown at air-liquid interface  
The simplest option is the standard submerged two-dimensional cell culture 
characterized by low cost and high-throughput. However, these standard submerged 
cell cultures do not represent the lung physiology such as the cells exposure to air. 
The complexity of in vitro models can then be enhanced with the addition of 
characteristics that progressively correspond with the human condition. Examples 
of such models include co-cultures, consisting of two or more cell types in one well, 
and three-dimensional (3D) cultures. By increasing the complexity of models, the 
physiological relevance generally increases and this entails that also the quality and 
the reliability of data that can be obtained from these more complex models can be 
significantly improved. In line with the complexity of models and the physiological 




Figure 4.  Respiratory models available from simple to complex (taken from Lacroix G., 2018) 
Cell lines: cell lines are usually obtained by transforming primary cultures of 
epithelial cells, using viral vectors (e.g. the large T-antigen of the SV40 or human 
papillomavirus) (Mathias et al., 1996). Usually, the continuous cell cultures are 
more reproducible and simpler to use than primary cell cultures: they are easier to 
handle, do not display inter-donor variability and have a prolonged life span. 
However, they often do not have the differentiated morphology and the biochemical 
characteristics of the original tissue (Hiemstra et al., 2018). 
The differentiation, such as the formation of cilia, the production of surfactants and 
mucus, the expression of transporters and proteins may be affected or reduced under 
submerged culture conditions, the passage number of the cells, cell seeding density, 
composition of the culture medium and the time in culture (Forbes & Ehrhardt, 
2005).  
For this reason, it is important to qualify cell cultures by assessing the extent of 
correlation with the in vivo situation in humans. Many cell lines from different part 
of the respiratory system are available.  
 
A549 Cell line. The A549 together with NCI-H441 are human pulmonary epithelial 
cell lines widely used as models for the alveolar epithelium for biopharmaceutical 
research (Ehrhardt et al., 2008; Salomon et al., 2014). 
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A549 is probably the most frequently used alveolar epithelial cell line. It is derived 
from human lung adenocarcinoma and when they are grown on filter inserts they 
have a morphology similar to alveolar type II cells. A549 cells contain 
multilamellar cytoplasmic inclusion bodies, like those typically found in human 
lung ATII cells, although these hallmarks disappear as culture time increases. The 
cells synthesize lecithin with a high percentage of desaturated fatty acids via the 
cytidine diphosphocholine pathway and therefore they have been used to study the 
regulation of pulmonary surfactants synthesis (Lieber et al., 1976). These cells do 
not form tight monolayers of polarised cells, due to the lack of capacity to form 
functional tight junctions (Foster et al., 1998). 
A549 cells might be a useful model in other areas of biopharmaceutical research, 
including metabolism studies or cytotoxicity studies for various substances. This 
cell lines possess P450 IA1 and P450 IIB6. These isozymes are significant due to 
their possible role in bioactivation of pro-carcinogens which may lead to lung 
cancer 
 
NCI-H441 human bronchiolar epithelial cells. NCI-H441 is a human epithelial cell 
line, isolated from a papillary adenocarcinoma of the lung. They are capable of 
forming a polarised monolayer with tight junctions, showing characteristic of both 
AT-II and bronchiolar Clara cells (Shlyonsky et al., 2005). This cell line 
functionally expresses P-glycoprotein and several members of the organic cation 
transporter family (Salomon et al., 2014). Therefore, the NCI-H441 cells cultured 
at an air-liquid interface could replicate the phenotypic and functional ion transport 
characteristics of primary cultures of human type II alveolar epithelial cells, but the 
culture conditions strongly influence the morphological, phenotypic and functional 
characteristics of the model (Ren et al., 2016). 
The Calu-3 and 16HBE14o cell lines, two immortalized human bronchial epithelial 
cell lines, have been suggested as suitable models to investigate the airway 
epithelial barrier function (i.e., tight junction properties) (Wan et al., 2000; Winton 
et al., 1998).  
Calu-3 cell line. The Calu-3 is an adenocarcinoma cell line of sub-mucosal 
glandular epithelial origin, comprising a mixed phenotype of ciliated and secretory 
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cells (Mathias et al., 2002). The Calu-3cells form in vitro polarized and well 
differentiated monolayers, with tight junctions, and they can be cultured at the air–
liquid interface with a morphology similar to in vivo bronchial epithelial cells. It 
has been reported that the use of submerged culture conditions may reduce the level 
of differentiated morphology expressed by Calu-3 cells (Florea et al., 2003; Foster 
et al., 2000). 
 
16HBE14o. The 16HBE14o cell line, originally developed by SV40 large T antigen 
transformation of normal bronchial epithelial cells, are non-ciliated, but in culture 
they are able to form functional tight junctions and to express a wide range of 
transporters. Even if this cell line is not capable of generating the desired phenotype 
at the air-interface, it has been used for drug absorption and drug/epithelial 
interaction studies (Manford et al., 2005). 
 
BEAS-2B. The BEAS-2B cell line was originally developed by immortalization of 
normal human bronchial epithelial cells using AD12-SV40 virus Another cell line 
frequently used to study epithelial cell structure and function, metabolism, cytokine 
regulation and interaction of xenobiotics is the Bronchial epithelial cell line (BEAS-
2B), but since BEAS-2B cells do not generate tight junctions, the use of this cell 
line in drug permeability/transport studies is limited (Noah et al., 1995). 
 
Primary cell cultures: The cultures of primary cells presents characteristics closer 
to the in vivo situation, and therefore they can represent a good model for the drug 
transport and toxicity studies. However, primary cells from animals or humans have 
a limited lifespan in culture; in addition, scarce tissue availability and time-
consuming isolation procedures are hurdles that need to be considered (Haghi et al., 
2014). Primary airway epithelial cells may be isolated from bronchial biopsies 
during bronchoscopy and cultured on porous supports at an air-liquid interface 
(ALI) resulting in a polarized muco-ciliary differentiated airway epithelial cells 
(Fulcher & Randell, 2013).   
Although methods for isolating and culturing adult rat, murine type II cells and fetal 
human type II cells have been available for years, only limited success has been 
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achieved in maintaining the differentiated functions of adult human alveolar 
epithelial cells in primary cultures (J. Wang et al., 2007). For example, alveolar 
epithelium is composed of structural type I and surfactant producing type II cells 
(Fehrenbach, 2001). Isolation and culture of type II human alveolar cells from 
healthy human lungs are able to generate confluent monolayers of cells expressing 
tight junctional proteins (Elbert et al., 1999). However, over time these type II cells 
change their morphology and develop a type I-like phenotype (S. Wang & 
Hubmayr, 2011). Despite the disadvantages that primary cultures possess, an 
advantage of using primary cultures is that they provide the closest in vitro 
representation of the native epithelium. 
Models of tracheobronchial epithelium from primary human airway epithelia have 
not been widely used so far to assess transport, because primary cultures represent 
a heterogeneous population of different cell types and therefore development of the 
model results to be time consuming and shows great variability (Forbes & Ehrhardt, 
2005).  
For over a century, traditional 2D cell cultures have been used in drug discovery. 
There is increasing evidence that the cell cultures as thin monolayers on plastic 
surfaces under submerged condition (the traditional 2D model) do not adequately 
enable human-relevant studies of cell behavior. These traditional models do not 
take into consideration the contributions of different cell types within the airway 
microenvironment, such as fibroblasts, endothelial cells, and immune cells that can 
be responsible of exposure outcomes. Thus, to achieve greater physiological 
relevance, other relevant airway cell types must be incorporated into 3D and 
organotypic in vitro models (Faber & McCullough, 2018). 
This comprehension has accelerated the development of more complex 3D models, 
where cells grow in multiple layers, better reflecting the normal cell interactions 
that occur in their natural environment.  
In these models, multiple epithelial and non-epithelial cell types, plus an 
extracellular matrix that contributes regulate cell behavior, are represented. 
Examples of such 3D models are organoid or spheroid cultures, as well as various 
dynamic air-liquid interface (ALI) models (e.g., lung on a chip). 
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The most recent bronchial ALI models represent a fully differentiated epithelium 
with more than one cell type (ciliated cells, goblet cells, and basal cells) that are 
often combined with immunocompetent cells (dendritic cells, macrophages, 
neutrophils) (Upadhyay & Palmberg, 2018). ALI systems therefore have the 
potential to conceptually provide relevant data since it is possible to construct them 
from human-derived cells and create modeling scenarios that are close to the in vivo 
situation. Recently, ready-to-use cultures of primary epithelial cells have been made 
commercially available (e.g. Epiairway™ or MucilAir™, Mattek Corporation© 
and Epithelix, respectively). However, these models are still in their infancy and 
they have not yet undergone a proper qualification process; for this reason, not 
many data are currently available in the public domain. 
Briefly, to produce the cell cultures, airway cells are obtained from healthy patients 
undergoing surgical lung lobectomy. The epithelial cells are isolated by enzymatic 
digestion, amplified and cultured directly on the microporous membrane of 
Transwell inserts. The cultures are grown in a commercially available defined 
airway culture medium. Once confluent, the cultures are switched to ALI. After 3–
4 weeks of culture, the epithelium becomes fully differentiated (Lacroix et al., 
2018).  
The complexity of the in vitro models of human airways is due to the presence of 
different cell types.  In this regard, SmallAir™, with 17% Club cells and 2% goblet 
cells, replicates better the morphology and function of the human small airways in 
vitro. (S. Huang et al., 2017). Furthermore, SmallAir™ contains basal cells and 
ciliated cells, showing cilia beating and muco-ciliary clearance. Therefore, these 
features make the SmallAirTM a unique and powerful tool for studying the 
physiology and function of small airways and it should provide new approach for 
lung diseases assessment and drug development (Lacroix et al., 2018).  
 
Lung-on-a-chip 
Most in vitro models are two-dimensional (2D) and therefore do not mimic the 
inherently complex nature of tissues. For exemple, intracellular signaling pathways 
are affected by the loss polarity when grown in 2D culture. These model do not 
recreate the active tissue-tissue interface between the micro-vascular endothelium 
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and parenchymale tissues where transport of fluids, nutrient and regulatory factors 
take place. Moreovere, they do not allow the application of dynamic mechanical 
forces that are critical for the development and fucntion of specific tissues (Huh et 
al., 2010). Recently, the integration of microfluidic with advanced biological 
approaches such as organoids, referred as organ-on-a-chip models, have been 
developed and extensively investigated. 
Lung-on-a-chip is a micro-engineered cell culture model that replicates the 
microarchitecture, breathing movements and primary physiological functions of the 
human lung (Huh et al., 2010).  This model is representing a new approach with 
strong potential to study the complex pathophysiology of lung diseases and improve 
the drug development (Shrestha et al., 2020). Typically, they are  created in 
microfabricated polymeric devices consisting of multiple layers of cell culture 
chambers to mimic three-dimensional micro-architecture of the tracheobronchial 
airways and alveoli. (Clippinger, Allen, Jarabek, et al., 2018). A typical lung-on-a-
chip is represented in Figure 5. The device structure allows co-cultures of human 
alveolar epithelial cells and pulmonary microvascular endothelial cells on the 
opposite sides of a membrane.  A computer-controlled cyclic vacuum system can 
mimic physiological breathing motions and concomitant tissue deformation (Huh 
et al., 2010).  
 
 
Figure 5. Representation of a lung-on-a-chip structure. A. Image of a polymeric device. B. Structure 
of a lung-on-a-chip: human alveolar epithelial cells and pulmonary microvascular 
endothelial cells are co-cultures on the opposite sides of a membrane. C.  A computer-
controlled cyclic vacuum system can mimic physiological breathing motions and 





2.5 Lung Toxicity 
As previously mentioned, the unacceptable toxicity associated with inhaled 
therapies represents the major obstacle in the development of inhaled drug (Cook 
et al., 2014). Respiratory toxicities are typically identified at a relatively late stage 
in preclinical testing. Therefore, during the development of new molecules, an early 
identification and prediction of potential lung toxicity would help in reducing the 
attrition in drug research and development, with a possible impact on the 3Rs too. 
The pathophysiological mechanisms associated with pulmonary tissue damage by 
the use of xenobiotics are diverse, probably due to the heterogeneity of the lung 
composition with many different cell types, each one with different sensibility to 
toxic agents  (Castell et al., 2005). Pulmonary drug toxicity may result from a direct 
or indirect drug effect. To date, more than 380 medications are known to cause 
drug-induced respiratory diseases (Fröhlich, 2017). 
Drugs with high potential to cause severe lung toxicity belong to very different 
chemical classes and therapeutic categories, including but not limited to: i) 
chemostatic (i.e. bleomycin, busulfan, and cyclophosphamide), ii) cardiovascular 
drugs (i.e. amiodarone and hydroxymethylglutaryl-CoA reductase inhibitors), iii) 
anti-inflammatory drugs (i.e. aspirin, methotrexate, gold, penicillamine, 
azathioprine, sulfasalazine), and antimicrobials (e.g. nitrofurantoin, amphotericin 
B, and sulphonamides). 
The accumulation in the lung and the lung-specific bioactivation may play a crucial 
role in the toxic effect. Due to its high incidence and high mortality of 40–50%, 
amiodarone-induced lung disease is one of the best-studied (Fröhlich, 2017). 
Various respiratory cells can be used to screen the cytotoxicity of a specific drug to 
lung cells. In general, A549 cells is a suitable cell line because their cytochromes 
(CYPs) enzyme expression pattern is more similar to the in vivo situation (Castell 
et al., 2005).  
Furthermore, a more relevant exposure systems, such as air-liquid interface culture 
with exposure to the formulation as aerosol or small treatment volume, may 




2.6 Factors affecting drug delivery to the lungs  
The evaluation of in vivo events post-deposition of the compound such as the lung 
distribution and pulmonary pharmacokinetics needs to consider that the lung has 
several efficient defence mechanisms that have the function to eliminate the 
exogenous substances, including inhaled therapeutic agents. The drug disposition 
in the lung is the result of the kinetics of absorption and non-absorptive clearance 
mechanisms.  As shown in Figure 6, different events can occur after the inhalation 
of a compound.  Most of the lung absorption takes place in the alveolar region, 
where a thin (approximately 1 µm) and large (approximately 140 m2) epithelium is 
present, to the pulmonary blood circulation. Part of the absorption can occur in the 




Figure 6.  Mechanism following inhalation and lung deposition (MC= Muco-ciliary Clearance; 
GIT= Gastrointestinal tract) (taken from Sakagami M., 2006) 
 
An inhaled substance may be eliminated from the lung by different non-absorptive 
mechanisms such the muco-ciliary or cough clearance into the gastrointestinal tract, 
by phagocytosis and/or metabolism in the mucus or lung tissue, reducing the 




2.6.1 The Muco-ciliary Clearance (MCC) 
The airways, from the nose to the alveoli are continuously exposed to pathogenic 
agents, particulates and gaseous material with potentially harmful effect. Therefore,  
a series of defence mechanisms are in place to protect the respiratory tract from 
these insults. The upper airways protect the lung with the anatomical barriers. 
Factors such as the mucus layer, macrophages, alveolar epithelium and the basal 
membrane can inhibit drug permeation into the circulation, associated with the 
cough reflex and muco-ciliary clearance with enzymes and immunoglobulin A. 
Furthermore, drug availability can be affected by the cellular uptake pathways, 
proteolytic degradation and surfactant interaction (Nicod, 2005). The inhaled drugs 
have to overcome these defence systems to ensure efficient drug deposition as well 
as retention in and absorption from the lung. 
The MCC is the primary innate defence mechanism of the lung. This is the process 
of physically eliminating the particles from the lung into the gastrointestinal tract 
by the coordinate interaction of the air surface liquid (ASL) and cilia beating. 
The functional components are the protective mucous layer, the airway surface 
liquid layer, and the cilia on the surface of ciliated cells. 
The cilia are specialized organelles that beat in metachronal waves to propel 
pathogens and inhaled particles trapped in the mucous layer out of the airways. The 
cilia beating is regulated by multiple physiological factors. 
The adult lung is estimated to contain ∼3 × 1012 total motile cilia, 6.5 to 7 µm long 
with a diameter of 0.1 µm. The core structure is the highly conserved axoneme that 
is extended from the basal body in the apical region of ciliated cells into the peri-
ciliary liquid. The ciliary axoneme (Figure 7) consists of nine outer doublet 
microtubules surrounding two central single microtubules.  
The cilia of the airways beat in a coordinated fashion that results in metachronal 
waves. The basal CBF ranges between 10 and 20 Hz (Satir & Christensen, 2007), 
yielding a muco-ciliary clearance velocity of ∼5.5 mm/min (Hofmann & 
Asgharian, 2003). The cilia beating frequency (CBF) is stimulated by β-adrenergic 
agonists, intracellular increase cAMP and cGMP and intracellular increase in Ca2+  
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(Bustamante-Marin & Ostrowski, 2017). The CBF can also be affected by pH 
changes and temperature because there is an optimal temperature for the enzymatic 
hydrolysis of ATP, with low temperatures decreasing the CBF. 
 
 
Figure 7. Cilia Axonema structure. The core structure is the axonemal with the characteristic 9+2 
pattern consisting of nine peripheral doublets microtubules surrounding a central pair of 
single microtubules (taken from Bustamante-Marine X.M., 2017).  
 
The standard measurement of MCC rates in humans requires the inhalation of a 
non-permeating radiolabelled marker. This method is not suitable for routine 
experimental studies, therefore, various methods have been used to study MCC in 
many different animal or ex-vivo models (Bustamante-Marin & Ostrowski, 2017). 
The recent models of differentiated human airways cultures, such ALI 3D models, 
have shown to be able to maintaining the coordinated activity, providing a valid 
tool to monitor the MCC. Impaired MCC is a feature of many airway diseases, 
including both genetic and acquired disorders. For example, in cystic fibrosis, 
mutations in the cystic fibrosis transmembrane conductance regulator protein result 
in a viscous, thick mucus that cannot be easily cleared, leading to repeated 
infections, bronchiectasis, and, eventually, respiratory failure. More in detail, the 
cystic fibrosis is caused by mutations in CFTR, a gene encoding an ion channel 
[cystic fibrosis transmembrane conductance regulator (CFTR)] that transports 
chloride and bicarbonate across epithelial cell membranes. Lung disease is 
37 
 
considered the cause of most mortality in people with CF and it is provoked by a 
host defense impairment which leads to bacterial infections (Hoegger et al., 2015). 
Ballard and colleagues pioneered the use of ex vivo pig tracheas for studies of MCC 
and Joo N.S.(Ballard et al., 2002; Joo et al., 2016) and colleagues extended this 
approach to the ex vivo ferret trachea. 
Muco-ciliary dysfunction is also a major component of other diseases, including 
COPD and asthma.  
Therefore, there is a high interest in better understanding the MCC for the 
development of therapeutic approaches to improve ciliary clearance in patients. 
The MCC and therefore the permanence time of an inhaled drug in the lungs is a 
factor that affect the drug absorption.  
 
2.6.2 Phagocytosis by Alveolar Macrophages  
In the alveoli region, the alveolar macrophages (AM) form the major defence to the 
transport of macromolecules from the lungs into the bloodstream, particularly for 
medium to large-sized proteins  (Lombry et al., 2004). Macrophages are a key 
component of the primary innate immune response and are present in almost all 
tissues of the body. In the lung, they are the most abundant immune cell type present 
under homoeostatic conditions (Byrne et al., 2015). 
They phagocyte insoluble particles that are deposited in the alveolar region and 
then they are removed by the lymphatic system or moved into the ciliated airways 
and eliminated via the muco-ciliary clearance (Labiris & Dolovich, 2003). 
 
2.6.3 Lung metabolism 
Although the lungs have the primary function of gas exchangers, they also perform 
several important non-respiratory functions. During the breathing, the respiratory 
tract is frequently exposed to environmental toxicants and carcinogens and it plays 
an important role in their detoxification. The same enzymes involved in the 
detoxification process may also contribute to the metabolism and elimination of 
inhaled, orally and intravenously administered drugs (Yilmaz et al., 2018). Some 
inhaled drugs such as theophylline, salmeterol, isoprenaline, budesonide, and 
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ciclesonide have been found to undergo significant metabolism in the lung (Joseph 
et al., 2013). Every compound administered intravenously, intramuscularly, 
subcutaneously or topically circulates through the lung before reaching the liver 
and therefore it may be subject to the lung metabolism (Yilmaz et al., 2018).  
All metabolic enzymes found in the liver are also present in the lung, although at a 
lower level. For example, cytochrome P450 is 5–20 times lower in the lung 
compared to the liver. Phase 1 cytochrome P450 (CYP450) enzymes, flavin-
containing monooxygenases (FMO),  monoamine oxidase (MAO), aldehyde 
dehydrogenase,  NADPH-CYP450 reductase, for example, are all present in the 
lung (Labiris & Dolovich, 2003). The enzyme involved in the drug metabolism are 
shown in the Figure 8. 
 
 
Figure 8.  Metabolic pathways and the role of efflux transporters (taken from Mortens N.P., 2014. 
The human lung, however, appears to be a poor site for sulphation.  
Proteins and peptides undergo hydrolysis by the proteases present in the lung. 
Sources for the proteases are the alveolar macrophages and other inflammatory 
cells, such as neutrophils. Therefore, the combined administration of proteins and 
peptides with protease inhibitors, such as bacitracin and sodium glycholate, can 
reduce the metabolism and increase the lung absorption (Labiris & Dolovich, 2003).  




Type II alveolar epithelial cells express enzymes required for metabolism, such as 
cytochrome P 450 , but type I cells are thought to have little capacity for metabolism 
(Mortensen & Hickey, 2014). 
Bio- transformation occurring in the lungs can be exploited in order to improve 
airway selectivity and minimize systemic side-effects of some inhaled drugs, 
designed as prodrug.  
For example, the prodrug beclomethasone dipropionate is metabolized to the more 
active 17-beclamethasone monopropionate by esterases in the lungs, reducing the 
side-effects in the oropharyngeal tract.  
Metabolism of inhaled chemicals is not always beneficial. For example, some 
innocuous chemicals in cigarette smoke are metabolized into potential carcinogens 
by the lung (Joseph et al., 2013). 
Regarding the expression of metabolising enzymes in vitro cell line, the principal 
phase I metabolising enzyme, cytochrome P450 (CYP) has been studied in A549  
(Foster et al., 1998), Calu-3 (Foster et al., 2000), BEAS-2B (Garcia-Canton et al., 
2013), but published data are still limited in this area. A recent review observes that 
in the several substructures and within them the various cell types possess a 
different pattern of xenobiotic-metabolizing enzymes (Oesch et al., 2019). 
 
2.7 Mechanisms of drug transport across the lung barrier 
The pulmonary epithelium is the most significant barrier to absorption. It separates 
the air-filled compartment of the respiratory system from the aqueous interstitial 
compartment and at the same time, it regulates the exchange of solutes and water 
between these compartments.  
The two cell types in the alveolar epithelium form a narrow band formed by tight 
junctions (TJ) between the adjacent squamous alveolar type I (AT-I) cells and much 
broader TJ complexes between  adjacent AT-I and the cuboidal alveolar type II 
(AT-II) cells. This reflects the heterogeneity of claudin (cldn) expression in alveolar 
epithelial cells. Both alveolar epithelial cell types express cldn3, cldn4 and the 







Figure 9.  Structure of alveolar epithelium. The tight junctions between adjacent AT-I cells are 
narrower than those between AT-I and AT-II cells (taken from Wittekindt., 2017). 
The process of absorption is described in Figure 10 and it can occur via passive 
diffusion or carrier-mediated active transport via paracellular or transcellular 
pathway depending on the drug and site of absorption (Liu et al., 2013) 
 
 
Figure 10. Epithelium drug transport mechanisms: a. Transellular diffusion, b. Paracallular 
transport, c. Vesicle mediated transport, and d. Carrier mediated transport (taken from 
(Ghadiri et al., 2019) ). 
 
Passive transport: Most exogenous macromolecules are thought to be absorbed 
from the airspaces non-specifically through tight junctions and via endocytic 
vesicles  (Patton et al., 2004).  
Small, lipophilic molecules and compounds are generally absorbed via transcellular 
diffusion, in which they pass from the apical to the basolateral side by traveling 
through the cellular membrane. The hydrophilic molecules may cross the 
epithelium via the paracellular route, which they pass through aqueous pores in the 
intercellular junction. For small hydrophilic molecules, molecular weight and 
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degree of ionization seem to affect the absorption rate, due to the interaction with 
the proteins and lipids forming the pore. Because a solute tends to pass from a point 
of higher concentration to a point of lower concentration by passive diffusion, the 
flux through the membrane can be calculated as the net number of passing moles 
per unit area in unit time perpendicular to unit area and it is represented by the 












Eq. 1. dm = moles of substance, A = unit area, dt = unit time, V = volume, dc = 
concentration of substance (Baldan, 2017). 
Some interspecies differences are noted for water-soluble drugs, whereas the rate 
of absorption of lipophilic compounds is about the same  (Schanker et al., 1986). 
This can be due to inter-species differences in alveolar pore number and pore size 
(Manford et al., 2005). 
The existence of membrane vesicles within the alveolar endothelial and epithelial 
type I cells has long been recognized. In particular, the majority of the vesicles are 
non-coated and morphologically classified as caveolae (Gumbleton, 2001). The 
general view is that alveolar vesicle-mediated trafficking across the air-blood 
barrier works as a minor pathway in protein absorption (Gumbleton, 2001; Patton, 
1996). 
 
Active absorption: A number of compounds undergo active or carrier-mediated 
transport. This transport moves molecules against the concentration gradient; as 
such, it is energy-dependent and it can be inhibited by competitor compounds with 
similar structural characteristics (Patton J.S., 1996).  The absorption rates of 
molecules transported by this way are saturable, such that the absorbed percentage 
decreases by increasing concentration. The active absorption depends on the lung 
regional expression of receptors or transporters (Liu et al., 2013). 
The lungs express a broad range of both uptake and efflux transporters (Bosquillon, 
2010), whose role on the disposition of inhaled drugs has received little attention 
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so far. Active transport may affect the permanence time of a drug on the epithelium 
and therefore it affects the absorption kinetic. Lung transporters might be involved 
in the uptake of drugs from systemic circulation, and their possible accumulation in 
the lung, causing pulmonary toxicity or affecting the drug pharmacodynamics. 
(Haghi, 2014). 
The most notable among the transporters is the efflux transporter P-gp. Other 
transporters include the breast cancer resistance protein (BCRP), the multidrug 
resistance-related protein (MRP), the OCT/Ns organic anion transporters (OAT), 




P-glycoprotein is an efflux transporter encoded by the MDR1 (multi drug 
resistance) gene. P-gp substrates cover a broad range of drug classes, 
although many are lipophilic or large amphiphilic molecules containing 
electronegative groups that can form hydrogen bonds. The functionality of 
P-gp is usually assessed by measuring the bidirectional efflux ratio (i.e. 
basal-to-apical:apical-to-basal) of a substrate such as rhodamin 123 or 
digoxin. Digoxin is not entirely selective for P-gp as it is also a substrate 
for organic anion transporting polypeptide transporters (Madlova M., 
2009) 
The P-gp is found in bronchial cell lines (e.g. Calu-3) and NHBE cells on 
the apical surface, similarly to human alveolar epithelial cells (Haghi 
M.,2014), as well as in Caco-2 cell line.  
 MRP 
Multidrug resistance-related proteins belong to the adenosine 
triphosphate binding cassette superfamily of membrane transporters 
ABC superfamily that obtain the energy by ATP hydrolysis (Scheffer et 
al., 2002).  
MRPs are responsible for efflux of amphipathic anions, glutathione S-
conjugated drugs and MRP1 expression showed regional difference and 
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its high expression in bronchi and alveoli may play a role as defense 
mechanism (Haghi et al., 2014).  
MRP expression has been demonstrated in the whole lung, in the apical 
or basal surface of primary epithelial cells isolated and cultured from 
human lung samples and in immortalized cell lines such as Calu-3 (Haghi 
et al., 2014). 
 
 BCRP 
Breast cancer resistant proteins act as an efflux transporter with a broad 
range of substrates. It is the third most abundant transporter expressed in 
the human lung and it has been showed to be involved in the transport of 
beclomethasone, ciclesonide, mometasone and ciprofloxacin. Moderate 
expression levels of BCRP have been observed in primary bronchial 
epithelial cells, whereas slightly lower level were observed in Calu-3 
cells (Haghi, 2014). 
 
 OCT, OCTN 
Organic cation transporters (OCT) are encoded by members of the solute 
carrier (SLC). The study of OCT transporters has been mainly focused 
on liver, kidneys, intestine and blood–brain barrier, but several common 
inhaled drugs positively charged at physiological pH, have been reported 
to interact with OCT (Salomon J.J. 2012) 
Differences have been observed in the OCT expression among different 
airway cell lines (Ingoglia et al., 2015). 
 OAT and OATP 
Organic anion transporters (OAT) and Organic anion transporting 
polypeptides (OATP) mediate adsorption and elimination of organic 
ions. Little or no expression of OATs in cultured bronchial epithelial and 
A549 cells was observed and the isoform OAT4 was the only transporter 
expressed exclusively in Calu-3 and 16HBE14o, suggesting a very 
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limited role of this transporter in the distribution of drugs in the lung 
(Haghi M., 2014). 
The OATPs transport (uptake and efflux) cationic, neutral, zwitterionic 
and anionic compounds. The OATPs share some substrates with P-gp, 
BCRP and MRP efflux transporters, therefore, the net disposition of a 
substrate molecule results from the combined contribution of all these 
transporters. In cultured bronchial epithelial cells, significant variation in 
the expression profiles of OATPs has been observed (Haghi M., 2014). 
 
 PEPT 
Oligopeptide transporters (PEPT1, PEPT2) transport a wide range of 
peptide and non-peptide drugs. In whole human lungs, only the 
expression of PEPT1 was reported. High expression of PEPT2 has been 
observed in all bronchial cell lines and primary bronchial and alveolar 
cells, while PET1 has been only expressed in Calu-3, 16HBE14o−, 
BEAS-2B and primary bronchial cells (Haghi M., 2014). 
 
Due to these different expression of transporters among the lung cell lines, it is 
necessary to take into consideration the possibility for many compounds to be 
delivered via multiple transporters. Therefore, the knowledge of transporters 
involved in the delivery of the drug of interest is important in the selection of 
immortalized lung cell lines for the better evaluation of compound transport 
(understanding and/or prediction in transport studies (Sakamoto A., 2015). 
2.8 Exposure System  
The purpose of delivery of inhaled substances to ALI cultures is to mimic the 
physiological processes happening in the lung. Aerosol effects on lung cells are 
often addressed in environmental toxicology (Aufderheide & Mohr, 2000; Bitterle 
et al., 2006). These investigation are mainly focused in evaluating long-term effects 




In contrast, pharmaceutical aerosols are aimed to deliver a specific dose of a given 
drug with a single administration. Drugs can be applied directly pipetting liquid 
formulation onto the ALI surface. Different methods have been used to expose cells 
cultured at ALI to aerosolized compounds either in dry powder form or by 
nebulization of solutions.  Drugs can be delivered through the air using drug 
delivery systems that mimic methods of deposition in different regions of the lung 
that can be integrated with the inhalers device for human administration. 
The Inertial impaction devices represent the basis on which many currently devices 
operate. It works on the principle of inertia; devices use a series of perpendicular 
nozzles, stages and collection plates to separate particles based upon the magnitude 
of their inertia (Karra et al., 2019) (Figure 11). 
 
Figure 11  Schematic representation of an inertial impaction. Arrows indicating airflow direction 
and particle separation based on inertial force, smaller particles are able to follow the 
airflow and therefore to continue to the next stage, whereas larger particles cannot due 
to the impact onto the surface (taken from Karra et al., 2019) 
This method is used in devices such as impingers (twin stage impinger and multi-
stage liquid impinger) (Figure 12) and impactors (Marple-Miller, Anderson 
cascade and next generation).  
An example of the use of this device for the ALI treatment is showed in Figure 12 





Figure 12. Schematic representation of a Multi-Stage Liquid Impinger (modified from Karra et al., 
2019). 
In electrostatic impaction devices, aerosolised particles are charged and flow 
through a humidifier. The deposition onto cells grown at ALI, is allowed by an 
electrode below the membrane which attract the charged particles (Figure 13). 
 
 
Figure 13. Schematic representation of the aerosol flow and particle deposition on the cell culture 
by electrostatic precipitation (modified  from Geiser et al., 2017) 
 
Sedimentation and diffusion devices are based on pressure differences to gently 
deposit compounds onto cells Figure 14. Particles are flowed through a tube at high 
pressure, and with low pressure outlets above wells housing insert with cell 
cultures. Air will naturally flow from an area of high to low pressure allowing 





Figure 14 Schematic representation of Pressure Derived Sedimentation and Diffusion devices 
(Taken from Karra et al., 2019). 
 
Commercial devices using pressure difference to deposit particles with airflow 
include CULTEX® (Figure 15) (Aufderheide et al., 2017), VITROCELL® 
(Mülhopt et al., 2016) (Figure 16 and Figure 17) and the PreciseInhale Xpose ALI 
(Figure 18) (Ji et al., 2017). 
 





Figure 16. Vitrocell®  exposure system for liquid aerosols with single droplet sedimentation 
(Taken from Vitrocell® Systems website). 
 
 
Figure 17. Vitrocell®  exposure system for dry powder can be applied from all commercially 
available inhalers or via direct dosing (Taken from Vitrocell® Systems website). 
 
 




3 AIM OF THE PROJECT 
The aim of this project was to evaluate the implementation of an Integrated Strategy 
(IS) to be applied to the drug development process of new and generic inhaled 
drugs. The idea was to integrate a preliminary screening method for the toxic 
potential evaluation with multidisciplinary approach applied to a unique 3D human 
lung model to evaluate different parameters such as toxicity, permeability through 
the tissue and inflammatory end points. These data should be integrated with in 
silico models, in order to obtain more predictive data for the selection of the best 
candidate to be progressed in pre-clinical investigations and in clinical trials.  This 
approach is expected to reduce the rate of failure in clinical trials. Furthermore, this 
approach is expected to have an impact on the number of animals to be used in in 
vivo studies for the regulatory submission. In this project the research has been 
focused on the following main aspects: 
1) Characterization of SmallAir™ cell model as potential in vitro model: 
 for respiratory acute toxicity test 
 for transport assessment of drug compounds and nicotine contained 
in the aerosol produced by e-cigarette  
 for inflammatory mediators and end-points evaluation 
 for the muco-ciliary clearance assessment 
2) Evaluation of a possible integrated approach consisting in the use of 
different parameters including toxicity, permeability data collection and 
MCC obtained in the in vitro SmallAir™ cell model together with in silico 




4 MATERIALS AND METHODS 
4.1 Materials 
SmallAir™ tissues and the specific SmallAir™ culture medium were obtained from 
Epithelix Sàrl (Switzerland). Each batch was supplied with a Certificate of Analysis 
reporting donor information (sex and age), cell information (cell type, data of 
seeding and data of air/liquid interface) and quality control results (sterility, 
Micoplasma, Trans-epithelial electrical resistance (TEER), cilia beating frequency, 
morphology, mucus and virus testing). The tissues were supplied cultured in 
Transwells, transferred in 24-well Falcon® plates (Corning Incorporated, 
Tewksbury, Massachusetts, USA).  
A549 cells, adenocarcinomic human alveolar basal epithelial cells (ATCC® CCL-
185™) were obtained from ATCC, Manassas, Virginia, USA. The cells were 
cultured on cell culture Corning™ T75 flasks (Corning Incorporated, Tewksbury, 
Massachusetts. USA) in RPMI Medium con GlutaMAX™ (Gibco®, Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). For the toxicity test cell were 
cultured in 96-well Falcon® plates (Corning Incorporated, Tewksbury, 
Massachusetts, USA). 
The permeability test substances Salbutamol (Lot. SC/48032), Budesonide 
(Certified Reference Material European Pharmacopoeia Reference Standard 
Council of Europe EDQMCS30026, Code: B1157300, Batch: 5.0), Fluticasone 
Propionate (Lot. ACR/2933), Propranolol Hydrochloride (Lot. BCBD8251V), 
Tiotropium Bromide Monohydrate (Lot. TIMHN0R802) and Theophylline (Lot. 
091M0214V), were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, 
Germany). Digoxin (ID D6003, Lot. BCBT0180). GF120918 (ID SRP010305e, 
Lot. FE650161550) was purchased from Sequoia Research Products Ltd 
(Pangbourne, UK). Dimethyl sulfoxide (DMSO) was purchased from Sigma-
Aldrich (Merck KGaA, Darmstadt, Germany). 
For the permeability nicotine test e-cigarettes and e-liquid were provided by a 
Client and details are not reported due to a disclosure agreement, Lucifer Yellow 
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(ID L0144, Lot. MKBB2552) was purchased from Sigma-Aldrich (Merck KGaA, 
Darmstadt, Germany).  
For the toxicity test, Dimithylamine (CAS 124-40-3), Glycidol (CAS 556-52-5), 
Dimethylamine (CAS 124-40-3), Hydrogen Peroxyde (CAS 7722-84-1) were 
purchased from Sigma-Aldrich Corporation (St. Louis, Missouri, USA).  
Recombinant human TGF-β (240-B) was purchased from R&D System, Inc., 
Minneapolis, USA. LPS (from P. aeruginosa Serotype 10) and Bleomycin were 
purchased form Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).  
Hank's Balanced Salt Solution (HBSS) was purchased from Sigma-Aldrich (Merck 
KGaA, Darmstadt, Germany). HBSSH was obtained by adding 10 and 12.5 mM 
HEPES (Gibco®, Thermo Fisher Scientific, Waltham, Massachusetts, USA) for 
toxicity test and permeability respectively. 
Resazurin for the toxicity was purchased from Sigma-Aldrich (Corporation, St. 
Louis, Missouri, USA).  
LDH-Glo™ Cytotoxicity Assay Kit (Promega Corporation. Madison, USA)  
For the cytokines analysis the MILLIPLEX MAP Human Cytokine/Chemokine 
Magnetic Bead Panel - Immunology Multiplex Assay (HCYTOMAG-60K-08) 
purchased from Merck KGaA, Darmstadt, Germany was used. For the SMAD2 
analysis used the L45MA-5 MULTI-ARRAY® 96 Sm Spot GAM Plate, purchased 
from Mesoscale Discovery, Maryland, USA was. 
For the evaluation of muco-ciliary clearance of ciliary movement, Micro particles 
based on polystyrene (BEADS) 30 µM, Forskolin (FRSK) and CFTRInh-172 were 
all purchased from Sigma-Aldrich Corporation (St. Louis, Missouri, USA).  
4.2 Test System 
4.2.1 SmallAir™ 3D Model   
The SmallAir™ tissues arrived in agar and they were transferred in a 24-well plate 
and cultured by ALI method (Air Liquid Interface) with 500μL of SmallAir™ 
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culture medium added with penicillin-streptomycin, in the basolateral 
compartment. Tissues were incubated at 37 °C in humidified air atmosphere 
containing 5% CO2 and 100 % humidity. The medium was changed every 2-3 days. 
The SmallAir™ presented native tissue properties such as a pseudostratified 
morphology, the presence of multiple cell types (mucus producing, goblet cells, 
ciliated cells with actively beating cilia, basal cells and club cells), functional tight 
junctions and mucus (Figure 19).  Each batch of tissues showed a TEER values 
above 200 Ω·cm2 and cilia beating frequency between 5 and 12 Hz. The 
experiments were conducted at least one week and 5 weeks after the arrival of the 
tissues. 
 
Figure 19. Schematic representation of SmallAir™. Taken from the Epithelix web site. 
 
4.2.2 A549 Cell Model   
The cells were cultured in adherent and submerged condition in RPMI Medium 
with GlutaMAX™ at 37 °C in humidified air atmosphere containing 5% CO2 and 
100 % humidity in cell culture flasks. Cell culture passages < 20 were used for the 
experiment. The day before the treatment 5000 cells/well of a 96-well plate were 
incubated at 37°C for approximately 24 hours.  
This model was used as further respiratory model in acute toxicity test.   
 
4.3 Methods 
4.3.1 Acute Toxicity Assay Protocol 
To avoid to generate and characterize an aerosol, the substances solutions were 
applied directly to the surface of SmallAir™ inserts and A549 cultures. Stock 
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solution were diluted in HBSSH (Hank’s Balanced Salt Solution with CaCl2 and 
HEPES 10mM).  
Approximately 24 hours before the treatment the inserts of SmallAir™ were 
visually inspected to insure the quality of the epithelia and rinsed apically with 
200 µL HBSSH. The washing step allows removing accumulated mucus and 
therefore minimizes the risks of interference with the test.  
Treatment Protocol for single dose Acute Toxicity Assay (Test 1 and Test 2) in 
SmallAir™: before the treatment the TEER of each SmallAir™ tissue was 
measured. Two different study design were evaluated as follow: Test 1 with a 
treatment period of 6 hours and Test 2 with a treatment period of 72 hours. A 
volume of 100 µL of Dimethylamine 0.73 mg/mL (Test 1) and of LPS 100 ng/mL, 
CdCl2 100 µM and TGF-β 10 ng/mL (Test 2) was applied onto the surface of 
tranwells  (in triplicate) and then incubated for 6 hours or 72 hours respectively at 
37 °C in humidified air atmosphere containing 5% CO2. After the incubation period, 
transwells and cell cultures were washed with HBSSH added with CaCl2 and a 
cytotoxicity assay was performed The TEER was measured after 24 hour and at the 
end of the treatment period and compared with TEER pre-treatment values.  
One tissue for each treatment of Test 2 was then processed for the histological 
observation. 
Treatment Protocol for Dose-related Acute Toxicity Assay (Test 3) in SmallAir™ 
and A549 cell model: Chemicals tested in the evaluation of acute toxicity after a 
single treatment of a range of concentration were selected from substances 
previously tested and published (Jackson et al., 2018), for which in vivo human or 
animal inhalation toxicity are available. In particular compounds chosen with the 







Table 1.  Compounds tested in the acute toxicity test with the respective toxicity classification.  







Glycidol  3 (H331) NA Yes 
Dimethylamine 4 IV Yes 
Diethylamine  4 IV Yes 
Hydrogen Peroxyde 
(H2O2), 
3 (H331) NA Yes 
a. GHS = Globally Harmonized System Acute Inhalation Toxicity classifications (Category 1 and 
2: Fatal if inhaled; Category 3: Toxic if inhaled; Category 4: Harmful if inhaled; Category 5: may 
be harmful if inhaled) 
b. EPA = Environmental Protection Agency Acute Inhalation Toxicity classifications  (Category I: 
Fatal if inhaled; Category II: may be fatal if inhaled; Category III: Harmful if inhaled; Category 
IV: caution) 
NA = not available  
 
The concentration range tested was selected on the basis of literature data 
(Jackson et al., 2018) and confirmed after preliminary test. In detail the 
concentrations were tested are reported in Table 2:  
Table 2.  Range of concentration test for each compound in the acute toxicity test both in the 3D 
SmallAir™model and A549 cell model. 
Test chemical Test chemical concentration  Test system  
Glycidol  1, 4 and 12 mg/mL SmallAir™ 
A549 
Dimethylamine 0.5, 1 and 1.5 mg/mL SmallAir™ 
A549 




5, 15 and 30 mg/mL SmallAir™ 
0.1, 0.5 and 1 mg/mL A549 
 
For the test, a volume of 30 µL of test chemical solution was applied onto the 
surface of transwells (in duplicate) and in the wells with A549 cultures (in triplicate) 
and then incubated for 3 hours at 37 °C in humidified air atmosphere containing 5% 
55 
 
CO2. After the incubation period, transwells and cell cultures were washed with 
HBSS added with CaCl2 and HEPES (10mM) and a cytotoxicity assay was 
performed. 
 
4.3.2 Viability Assay – Resazurin Test 
Resazurin is a non-toxic, cell permeable redox indicator that undergoes colorimetric 
change in response to cellular metabolic reduction. The reduced form, resorufin, is 
pink and highly fluorescent, and the intensity of fluorescence produced is 
proportional to the number of living cells (Figure 20). 
 
 
Figure 20. Structure of resazurin substrate and fluorescent resorufin product resulting from 
reduction in viable cells (taken from product sheet).  
 
To measure the cell viability, the SmallAir™ transwells were transferred in a new 
24 wells plate containing 500 µL of 6µM Resazurin in HBSS (1.25 mM CaCl2 and 
10 mM Hepes), a volume of 200 µL of the Resazurin solution was also applied onto 
the apical surface. For the A549 cultures, a volume of 200 µL of 6 µM Resazurin 
solution was applied into each well. The plates were then incubated for 1 h 37 °C 
in humidified air atmosphere containing 5% CO2. After the incubation, 100 µL of 
the apical solution was transferred in a 96 wells plate and the fluorescence of the 
transformed product was measured (Fluorimeter Tecan Infinite F200, Tecan, 
Männedorf; excitation filter = 535 nm; emission filter = 590 nm). As baseline 




The transwells were then transferred in a new 24 wells plate containing 700 µL of 
fresh medium and placed into the incubator (37 °C in humidified air atmosphere 
containing 5% CO2). 
 
Data handling: To determine the percentage of viability, the average absorbance 
values (A) of the replicate apical samples and baseline control were calculated using 
the following equation: 
 
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
𝐴 ( 𝑡𝑟𝑒𝑎𝑡𝑒𝑑) − 𝐴 (𝑏𝑎𝑠𝑒 𝑙𝑖𝑛𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
𝐴 (𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 ) − 𝐴 (𝑏𝑎𝑠𝑒 𝑙𝑖𝑛𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 100 
where A(treated) is the absorbance of compound treated tissue, A (base line 
control) is the absorbance of the non-transformed Resazurin solution, A (negative 
control) is the absorbance of the tissues treated with vehicle (HBSSH). 
Any possible effect on treatment group was assessed by the comparison with the 
negative control group. Statistical analysis was performed using the Student’s 
unpaired t- test. Viability in percentage was graphically represented with the more 
appropriate plot and reported in tables with individual values and group means ± 
standard error mean (SEM) for each test item tested.  
P-values <0.05 was considered statistically significant. Statistical analysis was 
performed using SAS v.9.4. No statistical analysis was performed for the Test 1, 
given the low number of replicate (duplicates). 
 
4.3.3 Trans-epithelial electrical resistance (TEER) measurement 
Trans-epithelial electrical resistance (TEER) is a widely accepted quantitative 
technique to measure the integrity of tight junction dynamics in monolayers cell 
culture models.  
TEER is the measurement of electrical resistance across a cellular monolayer and 
is a very sensitive and reliable method to confirm the integrity and permeability of 
the monolayer (Srinivasan et al., 2015). TEER measurements was performed using 
a Millipore Millicell-ERS cat. no. MERS 000 01 (Merck KGaA, Darmstadt) by 
placing electrodes on both sides of a cell layer grown on a semipermeable 
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membrane and measuring both current and voltage across the cell layer (Figure 21). 
TEER values were determined for all cultures before and after the experiments. In 
detail, for the TEER measurement of SmallAir™ a volume of 0.2 mL HBSSH and 
0.5 mL HBSSH in the apical and basolateral compartments, respectively was added.  
The TEER values were calculated as follows: the resistance of the culture 
membrane will be subtracted (100 Ω for SmallAir™ Insert) from the measured 
values and then normalized with the surface of the insert (0.33 cm2) and TEER was 
finally presented as Ohm·cm2 (Ω·cm2). 
 
Figure 21. Transepithelial/ transendothelial electrical resistance (TEER) measurement with 
chopstick electrodes (taken from Srinivasan et al., 2015). 
Statistical analysis was performed using the Student’s unpaired t- test. TEER in  
Ω·cm2 was graphically represented with the more appropriate plot and reported in 
tables with individual values and group means ± SEM for each test item tested.  
 
4.3.4 SmallAir™ Hystology 
Histology observation was performed after Toxicity Test 2 only. Tissues were 
rinsed in PBS and fixed by immersion in 4% formaldehyde solution for 30 min and 
then washed with HBSS with Ca2+/Mg2+.  For the dehydration process, tissues were 
placed in successive baths as follow: 
Ethanol 30%, 15 min 
Ethanol 50%, 15 min 
Ethanol 70%, 15 min 
Ethanol 90%, 15 min 
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Ethanol 100%, 30 min 
Xylene-Ethanol (1:1), 30 min 
Xylene 30 min 
Paraffin at 60°C, 1 hr 
Transwells were than embedded into paraffin, sectioned and processed for staining 
with Hematoxylin Eosin. Slides were evaluated by microcopical analysis. 
 
4.3.5 Permeability Assay 
4.3.5.1 Permeability studies in SmallAir™ - liquid treatment  
The aim of this assay was to determine passive cellular permeability (Papp) and 
P-gp activity through the human SmallAir™ cells.  
The permeability of the Salbutamol, Budesonide, Tiotropium Bromide, 
Theophylline and Digoxin on SmallAir™ tissues was assessed. Each compound 
was dissolved at 10 mM in DMSO and then diluted at 10 µM in HBSSH. 
The apical and basolateral compartments were the donor and acceptor 
compartments, respectively in A to B permeability and oppositely in B to A 
permeability (Figure 22).  
 
Figure 22. Schematic representation of permeably process (taken from Palumbo et al., 2008). 
In details, for the A to B permeability, a volume of 200 μL of compound 
formulations at 10 μM in HBSSH buffer was applied onto the donor (apical) 
compartment and a volume of 500 μL HBSSH was added into the acceptor 
(basolateral) compartment. To assay the permeability a volume of 100 μL from the 
acceptor compartment and a volume of 10 μL from the donor compartment after 60 
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min was sampled. The samples were analyzed by HPLC–MS to measure the drug 
content.  
For the B to A permeability, a volume of 500 μL of test compound formulation at 
10 μM in HBSSH buffer was applied into the donor (basolateral) compartment and 
a volume of 200 μL HBSSH into the acceptor (apical) compartment. To assay the 
permeability a volume of 10 μL from the acceptor compartment and 100μL from 
the donor compartment after 60 min was sampled. The samples were analyzed by 
HPLC–MS/MS to measure the drug content.  
Data Handling: For each treatment, the apparent permeability, Efflux Ratio and the 
Recovery was calculated. 
The apparent permeability (Papp) index is defined as the initial flux of compound 
through the membrane (normalized by membrane surface area and donor 
concentration) (Palumbo et al., 2008). It represent how likely is a compound to pass 
through the test system. 
The Papp values were calculated for direction [A to B] and [B to A], according to 































Were dQ/dt is the steady-state flux across the cell layer (the amount of test item 
expressed as area ratio), C0 is the initial concentration (mol/mL) in the donor 
chamber and A is the surface area of the filter (0.333 cm2 for 24 well plates). The 
Papp was expressed as nm/sec and average ± standard deviation (SD) for A to B 
and for B to A directions was calculated for each treatment. The Papp can be used 
to predict oral/intestinal bioavailability on the basis of a classification based on 





Table 3. Permeability classification: correlation between in vitro Papp and predicted in vivo 
absorption.  
In vitro Papp Predicted in vivo absorption 
Papp ≤ 10 nm/sec 0-20% (Low) 
10 nm/sec ≤Papp ≤ 100 nm/sec 20-70% (Medium) 
Papp > 100 nm/sec 70-100%  (High) 
 
The Efflux Ratio (ER) is calculated according the following equation: 
𝐸𝑓𝑓𝑙𝑢𝑥 𝑅𝑎𝑡𝑖𝑜 =
𝐴 𝑡𝑜 𝐵 𝑃𝑎𝑝𝑝
𝐵 𝑡𝑜 𝐴 𝑃𝑎𝑝𝑝
 
When a drug diffuses only by passive diffusion both A to B and B to A permeability 
should be similar and therefore the ER should results about 1. While, when a drug 
is the substrate of specific transporters, the permeability will result increased in the 
direction A to B if an uptake transport is involved or in B to A direction when an 
efflux pump is engaged. With an ER greater than 2 the compound might be 
considered substrate of efflux transporters such as P-gp, whereas with a ER lower 
than 2 is generally not considered substrate for these king of transporters.. 
4.3.5.2 Permeability Assay – aerosol treatment  
For the assessment of the permeability after aerosol treatment the CULTEX® RFS 
Compact (Cultex Laboratories GmbH, Hannover, Germany) has been evaluated as 
exposure device for nebulized formulation.  
The CULTEX® RFS Compact consists of two main parts, the aerosol-guiding 
module and the sampling module where 6 cell culture inserts can be allocated. The 
device expose 3 insert positions to the aerosol treatment and the remaining 3 insert 




Figure 23. Schematic representation of exposure module of the CULTEX® Compact device Cultex 
Laboratories GmbH, Hannover, Germany. 
 
For the application of a commercially available formulation for nebulizers, the 
CULTEX® device was connected to a simple nebulizer (Aerosol TurboBOY SX, 
Pari GmbH, Starnberg, Germany). 
Briefly, Broncovaleas® (4 mL at 5 mg/ml suspension for nebulization) and 
Budesonide Aircort® (2 mL at 0.5 mg/ml suspension for nebulization) were 
nebulized and the aerosol was applied onto the SmallAir™ tissues with a flux of 1 
ml/min. After the nebulization, samples of 100 µL of HBSSH from basolateral 
compartment and 10 µL (after the addition of 100 µL of HBSSH) from the apical 
compartment were collected. Samples were then analysed by a HPLC-MS/MS 
method for the quantification.   
In addition, the CULTEX® RFS Compact, connected to a Borgwaldt smoking 
machine LM1E (Borgwaldt KC, Hamburg, Germany), was used to design a 
protocol for the assessment of nicotine permeability after e-smoke exposure. Two 
experiments have been conducted with two different commercial e-cigarettes 
containing the same e-liquid.  Briefly, the e-cigarette was connected to the smoking 
machine (Figure 24) and the e-liquid aerosol (containing nicotine) and vehicle was 
distributed on the tissues following the CORESTA recommended puffing regime 
Method No.81 (CORESTA, 2015). A number of 16 puffs were taken with a puff 





Position of treatment exposure
Position of clear air exposure
62 
 
the e-liquid aerosol was diluted with regular air (1 L/min) before being sucked into 
the CULTEX® RFS compact via a vacuum pump with a flow rate of 
5 mL/min/insert.  Two transwells with SmallAir™ tissues and an insert without 
cells were exposed for each test. In test 2 two runs were conducted. The insert 
without cells was used as reference to quantify the amount of nicotine that has 
actually reached the tissues. In each experiment vehicle and e-liquid containing 
nicotine have been applied. In addition a positive control (H2O2 10%) was applied 
as liquid formulation.     
 
Figure 24. Image of the instrument set up for the assessment of nicotine permeability through the 
SmallAir™ tissues. CULTEX® RFS Compact, on the left, was connected to a Borgwaldt 
smoking machine LM1E  
 
For each test TEER before and after e-smoke exposure was assessed. After the e-
smoke exposure, cell viability by Resazurin test and the integrity of tissues by 
Yellow Luciferase Assay were assessed. At the end of the e-smoke exposure, one 
sample of 100 µL of medium from the sampling chamber was collected at different 
time points (2 and 5 minutes after the exposure). The concentration of nicotine was 
quantified by qualified method using liquid chromatography with tandem mass 
spectrometry detection (LC-MS/MS).  
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4.3.5.3 Luciferase Yellow Assay 
This assay allows to assess the paracellular permeability as indicator of the integrity 
of the tissues using the yellow luciferase marker (LY) and therefore allows to 
determine if the permeability is due to a damaged tissue or to a physiological 
transport. When the tissue is constituted by selective barrier sealed by tight junction, 
no or really low paracellular flux is present and the transcellular pathway is the only 
way to cross the tissue. Molecules as LY that are unable to pass a cell monolayer 
grown on microporous membranes by transcellular pathway can be used to evaluate 
the barrier status.  
LY permeability was measured in one direction, [A→B], at the end of incubation. 
Residual solutions in the apical compartment after the treatment was gently 
removed and 200 µL of donor working solution containing LY at 100 µM in culture 
medium were then added to the A compartment and 600 µL of receiver working 
solution (culture medium) to the B compartment. The cells were incubated at 37°C 
for 60 min. 
A volume of 100 µL from receiver wells, 100 µL/well of donor solution containing 
100 µM LY and 100 µL/well of Transport medium were transferred to 96-well 
clear bottom black plate (Nunc™ F96 MicroWell™ Black Polystyrene Plate, 
Thermo Fisher Scientific, Waltham, Massachusetts, USA). Fluorescence was 
measured by using a fluorescence plate reader (FLUOstar OPTIMA Microplate 
Reader, BMG LABTECH, Ortenberg, Germany), at Ex = 485 nm, Em = 535 nm. 
Data handling: The percent permeability from the fluorescence values was 
calculated as follows: 





Where RFU are the relative fluorescence unit values (subtracted by the background 
mean values); RFU apical is the mean value of the donor solution LY 100 µM.  
A % LY rejection >98% is considered acceptable, between 98% and 95% is 
considered acceptable with caution and < 95% is considered not acceptable. 
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4.3.5.4 Permeability Assay - NGI  
The regional deposition in the lung is determined by the aerodynamic diameter of 
the particles. Impactors are the instruments of choice for the in vitro assessment of 
delivery efficiency of inhalation products. The Next Generation Impactor (NGI) is 
a high performance cascade impactor with seven stages (Figure 25) and it operated 
at any inlet flow rate between 30 and 100 L/min with the cut sizes spanning a 
particle size range nominally from 0.25-µm to 11-µm aerodynamic diameter which 
are collected in specific cup. 
 
Figure 25. Next Generation Impactor in “open” position.   
One NGI cup was modified by creating holes in the cup where transwells were 
allocated as showed in Figure 26. A Volume of 500 µL of medium was transferred 
in each well. Two wells were used to allocate the SmallAir™ tissue transwells, 
while one well was occupied with a transwell without tissues in order to measure 
the total compound applied. The transwell without tissue was equipped with plain 
filter to collect the dose deposited. The efficiency of modified cup was checked 




Figure 26. Images of Next Generation Impactor Cup modified, with tissue insert allocated. A. Top 
View B. Side view.  
 
A preliminary test without tissues was performed to confirm that the same amount 
of compound was deposited in each well. This test was carried out as the final 
experiment except for adding filters in the empty transwells rather than the tissues. 
The modified cup was positioned at stage 3 place and three filters were inserted into 
the empty wells. Spiriva (Tiotropium Bromide) dry power inhaler (DPI) capsules 
and devices were used to test the modified cup. Prior to run the test, the Critical 
Flow Controller was adjusted to 39 L/min by using a calibration Dosage Unit 
Sampling Apparatus tube (DUSA tube) and then a Leak test was performed on the 
NGI impactor to verify eventual pressure leakage in the modified system. The NGI 
impactor was attached to the leak tester and a bung was placed into the throat to 
seal it.  A pressure of 5 kPa was initially applied before adjusting it to 4 kPa and the 
pressure was recorded after 20 seconds. The resulting leak rate need to be lower 
than 100 Pa/s to pass and it was calculated as follows:  
Leak rate = (4 - P recorded) x 1000/20.  
After the Leak test, the flow rate of the NGI impactor was checked to be at 39 L/min 
and then 5 Tiotropium Bromide (18 µg) capsules were fired into the NGI impactor. 
The filters were collected after the firing and they were placed into three 
scintillation vials with the addition of 1ml of diluent (10 mM Ammonium 
dihydrogen phosphate buffer pH 2.9/ Methanol 70/30 % v/v). The samples were 




1.7 ml/min and a column temperature of 40°C. To confirm the data reproducibility, 
the test was performed twice.   
The final test was performed at the same condition reported above with 2 
SmallAir™ transwells and 1 insert without tissue. After the treatment the 
SmallAir™ transwells were incubated at 37 °C in humidified air atmosphere 
containing 5% CO2 and 100 % humidity for 1 hour. After the incubation period, a 
sample of 100 µL of medium from each basolateral compartment was collected.  A 
volume of 100 µL of medium was added to the apical compartment to dissolve and 
collect the possible compound deposited onto the surface.  
4.3.6 Phospho-SMAD2 (p-SMAD2) measurement 
SmallAir™ cultures were treated with recombinant TGF-β (final concentration 
20 ng/ml) for 1 and 3 hours. A the end of the incubation period, the cells were lysed 
in complete TRIS lysis buffer and p-SMAD2 (at residues S465/S467) and total 
SMAD2 was measured with an MSD-based assay (L45MA-5 MULTI-ARRAY® 
96 Sm Spot GAM Plate, Meso Scale Discovery’s Assay). SMAD2 was analysed 
using two immune-assay in parallel: the capture antibody (against total SMAD2 
form) was common to the two assays, whereas the detection antibody was either 
anti-total SMAD2 or anti-phospho-SMAD2 (Ser465/467)-specific. The use of 
appropriate MSD microplates (96 well-small spot Goat Anti Mouse –GAM- plate) 
with carbon electrodes integrated into the bottom of each well and a detection 
antibody conjugated with electrochemiluminescent labels (SULFO-TAG™) 
provided a specific electrochemiluminescent signal proportional to the target of 
interest measurable using a MSD reader.   
Briefly, tissues were lysed in complete Tris lysis buffer and scraped after 1 hr 
incubation on ice. After a clearing step, protein concentration was assessed using 
BCA kit (Bicinchoninic Acid Assay protein determination kit) and the supernatant 
used immediately for SMAD2 analysis or stored at -80°C.  
GAM plates were blocked with 3% Blocker A in Tris Buffer Saline with Tween 20 
(TBST) for approximately 1 hour at RT, then the plate were coated with capture 
antibody [mouse anti-SMAD2/3 antibody (BD, 610843), 1:250 dilution] and 
incubated for 2hr. Tissue lysate (10µg) was transferred to MSD plates and incubated 
overnight at 4ºC. Detection antibodies (rabbit anti-total SMAD2, Thermo Fisher, 
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51-1300, 1:500 dilution or rabbit anti-phospho-SMAD2 (Merck Millipore, 04-953, 
antibody 1:50 dilution) were added to the MSD plate. After 2hr incubation, MSD 
Sulfo-Tag labeled anti-rabbit diluted 1:500 were added and incubated for 1hr. 1X 
Read Buffer was added and plates were read immediately in a MSD reader (e.g. 
MSD Sector 6000).  
Data handling: A semi-quantitative determination of pospho-SMAD2/SMAD2 
level was used, normalizing phospho-SMAD2 (pSMAD2) levels to total SMAD2 
levels (tSMAD2). Values are expressed as means ± standard error. 
Statistical analysis was performed using GraphPad Prism 8 or STATISTICA 10 by 
a One Way ANOVA followed by Post Hoc Fisher LSD test.  
4.3.7 Cytokines and pro-inflammatory mediators measurement. 
For the analysis of cytokines and pro-inflammatory mediators release, SmallAir™ 
cultures were treated in triplicate with a Bleomycin at concentration of 10, 30 and 
100 µM applied onto the surface (100 µL). 
Supernatant in the lower chamber was collected after 24 hours and 72 hours. The 
quantification of IL-6, RANTES, IP-10, ETXN, IL-4, MIP-1β, IL-8, GRO was 
performed using a Luminex bead-based Multiplex Assay (MILLIPLEX MAP 
Human Cytokine/Chemokine Magnetic Bead Panel - Immunology Multiplex 
Assay) according to manufacturer instructions.   
 
4.3.8 Lactate Dehydrogenase (LDH) assay 
Lactate Dehydrogenase (LDH) assessment was performed in the samples obtained 
from the medium of SmallAir™ cultures treated in triplicate with a Bleomycin at 
concentration of 10, 30 and 100 µM in the upper chamber for 24 hours and 72 hours.  
The LDH release was quantified using the LDH-Glo™ Cytotoxicity Assay. 
The LDH-Glo™ Cytotoxicity Assay provides a simple bioluminescent method for 
quantifying LDH release. The bright luminescent signal provides the sensitivity to 
determine cytotoxicity in 3D microtissue spheroids, microfluidic cell culture chips, 
primary cells and stem cells. The method is based on a bioluminescence reaction. 
LDH catalyzes the oxidation of lactate with concomitant reduction of NAD+ to 
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NADH. Reductase uses NADH and reductase substrate to generate luciferin, which 
is converted to a bioluminescent signal by Ultra-Glo™ rLuciferase (Figure 27).  
The light signal generated is proportional to the amount of LDH present. 
In the LDH-Glo™ Assay protocol, 25 µL LDH Detection Reagent (containing 
Lactate, NAD+, Reductase, Reductase Substrate and Ultra-Glo™ rLuciferase) was 
added to 25 µL sample of diluted cell culture media. After 1 hour of incubation at 
room temperature the luminescent signal generated was read by a luminometer 
(Victor³v, PerkinElmer, Waltham, Massachusetts, USA). 
 
Figure 27. Schematic representation of LDH-Glo™ cytotoxicity assay mechanism.. 
Data handling: results were expressed as fold increase compared to the negative.  
 
4.3.9 ROS measurement 
For the measurement of reactive oxygen species (ROS) released in the medium by 
the SmallAir™ after treatment with Bleomycin at concentration of 10, 30 and 
100 µM in for 24 hours and 72 hours, the ROS-Glo™ H2O2 Assay was used. This 
method is a homogeneous, rapid and sensitive luminescent assay that measures the 
level of the ROS hydrogen peroxide (H2O2). 
ROS generated in cells can act as signalling molecules and, in excess, can lead to 
cell damage or death (Wittmann et al., 2012). Among the several ROS that are 
generated in cell cultures, the H2O2 is the most convenient to assay because it has 
the longest half-life of all ROS in cultured cells. 
The ROS-Glo™ Assay mechanism for H2O2 measurement is shown in Figure 28. 
An H2O2 substrate reacts directly with H2O2 to generate a luciferin precursor. Upon 
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addition of ROS-Glo™ Detection Reagent containing Ultra-Glo™ Recombinant 
Luciferase and d-Cysteine, the precursor is converted to luciferin by the d-Cysteine, 




Figure 28. Schematic representation of ROS-Glo™ H2O2 Assay. 
In the ROS-Glo™ Assay protocol, 10 mM H2O2 Substrate provided in the kit was 
diluted to 100 µM with the H2O2 Substrate Dilution Buffer and added to the tissues 
after Bleomycin treatment at concentration of 25 µM  and incubated at 37 °C in 
humidified air atmosphere containing 5% CO2 and 100 % humidity for 1 hour. 
Then, a volume of 10 µL of medium sample from each treatment condition was 
transferred into a 96-well plate in duplicate. A volume of 10 µL of ROS-Glo™ 
Detection Solution was added to each well. The plate was incubated for 20 minutes 
at room temperature and the relative luminescence was measured using.a plate 
reader (CLARIOstar plate reader). 
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4.3.10 Muco-ciliary Clearance Assay 
For the evaluation of the MCC the following compounds were tested: Forskolin 3 
and 10 µM before and after treatment with CFTRInh-172 20 µM; Carbachol 10 µM 
before the treatment with CFTRInh-172 20 µM; Saline 3 %; LPS 100 ng/mL, 1 
µg/mL and 1 mg/mL; Salbutamol 10 µM; Budesonide 10 µM; Fluticasone 
Proprionate (FP) 10 µM; Theophylline 10 µM; Tiotropium Bromide 10 µM. 
The MCC was evaluated measuring the speed of the flow of the lining fluid on the 
surface of the SmallAir™ tissues after compound treatment. In particular, 30 µm 
polystyrene microbeads, diluted 1:25 in each test compound solution were added 
on the apical face of SmallAir™ at a volume of 30 µL and the movement of the 
microbeads was recorded with a 12 MPX f/1.7 Samsung S7 camera at 30 frames 
per second, on an inverted microscope (model Leica DML, Leica Microsystems 
S.r.l., Milan, Italy) with magnification 10X, at room temperature. 
Agonist and Ion Transport Inhibitors. To test the effect of agonist, such as Forskolin 
(FRSK) and Carbachol (CCH) and ion transport inhibitors (CFTRInh172) different 
study design were applied: 
- Test 1: Treatment with CFTRInh172 20 µM followed by the treatment with 
FRSK 3 µM and 10 µM; 
- Test 2: Treatment with agonist FRSK 3 µM and 10 µM followed by the 
treatment with CFTRInh172 20 µM; 
- Test 3: Treatment with agonist (CCH 10 µM) followed by the treatment 
with CFTRInh172 20 µM;  
For each tissues the baseline speed of the cilia was assessed with beads diluted in 
HBSSH in order to have a no-treated control to compare for the evaluation of the 
compound effect 
The video where captured at the following time points after treatment: immediately 
after treatment (T0), after 10 minutes (T10) and after 20 minutes (T20). 
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Drug compound treatment. Test 4: Each compound was tested at the concentration 
of 10 µM and videos were captured at T0, T10, T20, T30 and T40. While LPS and 
Saline 0.9 % and 3 % have been tested at T0 only. 
Data handling. Two different approaches were taken into consideration for the 
videos analysis, in order to individuate the more appropriate method of analysis:  an 
automatic methods and a manual methods. Then all videos were analysed using the 
manual method.   
4.3.10.1 Analysis method evaluation  
The automatic and manual methods have been applied to Test 1 and Test 2 for a 
comparison. At first the automatic method was considered in order to capture a high 
number of trajectories. Videos are analysed using ImageJ Software (Mosaic- 
Particle Tracker 2D/3D plugins) (Figure 29) and 50 frames at time (for at least of 
300 frames/video) were analysed.  
 
Figure 29. Example of trajectories selected by ImageJ (Mosaic-Particle Tracker 2D/3D Plugins).  
In the manual approach, 50 frames at time (for at least of 300 frames/video) were 
analysed using ImageJ Software (MTrackJ plugins) (Figure 30), tracking at least 




Figure 30. Example of trajectories selected by ImageJ (Mtrackj Plugins). 
Data handling: the coordinates of beads were measured at each frame (in automatic 
approach) or every 5 frames (in manual approach) and used for the speed 
measurement. The beads speed in mm/sec was calculated using an Excel Sheet 
applying the Pythagorean Theorem to measure the distance travelled by the bead. 
A Bürker Chamber was used to measure the ratio mm to pixels (mm/pixels) 
applying the following step.  The following equation was applied: 
 
where r = distance travelled by the bead in pixel; frame n = (number of the frame); 
frames per sec = number of frames taken per second (30); mm = measure length on 
Bürker Chamber in mm (0.2 mm); pixels = number of pixel in 0.2 mm. 
Statistical analysis was performed to evaluate the reliability of these approaches. 
At first, an analysis of number of frames captured for each trajectories by automatic 
method was conducted and a higher number of trajectories compared to the number 
of beads was observed. This was because the software showed to lose the tracking 
of beads therefore trajectories with a number of frame lower than 45 where 
excluded from the analysis. 
For each approach, averaged values of speed, for each trajectory, were analysed 
using an analysis of variance (ANOVA) followed by post-hoc Dunnett’s test. The 
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speed measured for each treatment and time point was compared to negative control 
(base-line control). Furthermore speed of beads after FRSK treatment versus 
CFTRInh-172 at 20 minutes and CFTRInh-172 versus FRSK at 20 minutes for Test 
1 and Test 2 respectively were compared. Bead speed was presented in graph and 
tables with group means ± SEM for each negative control and treatment groups. 
P-values <0.05 was considered statistically significant. Statistical analysis was 
performed using SAS v.9.4. 
Results obtained with automatic method was firstly compared with manual analysis 
and the manual approach was finally considered for the evaluation of MCC. For 
Test 1, Test 2 and Test 3 the statistical analysis describe above (ANOVA and post-
hoc Dunnett’s test) was conducted to compare each treatment versus the negative 
and the agonist versus inhibitor treatment for Test 1 and inhibitor versus agonist 
treatment for Test 2 and Test 3. 
For Test 4 each time point was analysed versus the negative control only. 
For the evaluation of the cilia beating synchronization the particle image 
velocimetry analysis of ImageJ Software (PIV plugins) was conducted.  
4.3.11 MPPD prediction analysis  
The multiple-path particle dosimetry model was used to integrate in vitro MCC 
result with the in silico method prediction. The parameters selected are reported in 
the Table 4. In addition to these parameters, additional parameters such as: 
- Airway Morphometry: Functional Residual Capacity (FRC); Volume, 
Upper Respiratory Tract (URT); 
-  Inhalation properties: Density, Aspect Ratio; 
- Exposure condition:  Acceleration of Gravity, Body Orientation, Aerosol 
Concentration, Breathing Frequency, Tidal Volume, Inspiration Fraction, 
Pause Fraction; 
- Deposition/Clearance: Fast Human Clearance Rate, Medium Human 
Clearance Rate, Slow Human Clearance Rate, Lymph Node Human 
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Clearance Rate, Rata Clearance Parameter (a, b, c, d), Lymph Node Rat 
Clearance Rate, Exposure Time Settings 
were left as default. 
Table 4. Parameters selected in the multiple-path particle dosimetry model 
Airway Morphometry 
Species Human 
Model Yeh / 5-lobe 
Inhalation properties (Aerosol) 
Diameter  3 µM 
Exposure condition 
Constant  Breathing Scenario Oral 
Deposition/Clearance 
Deposition + Clearance Tracheal Mucous Velocity 5.5 mm/sec for 
negative control (default); velocity expressed 
as mm/sec obtained in the MCC in vitro assay 
for the analysed compounds 
 
The parameter “Tracheal Mucous Velocity” was considered 5.5 mm/sec as default 
for the not treated tissues. Average tracheal mucus velocities in healthy non-
smokers, as measured by non-invasive radiological techniques, ranged from 4 to 6 
mm/min; consequently, the value of 5.5 is considered as adopted by both 
International Commission on Radiological Protection (ICRP, 1994) and National 
Council on Radiation Protection and Measurements (NCRP, 1997) committees 
(Hofmann & Asgharian, 2003).  
Data handling: the mucus velocity of 5.5 mm/min value was used to calculate a 
correction factor to be applied to the speed measured for the tissues compound 
treated. The following equations was used: 
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 =
5.5 𝑚𝑚/𝑠𝑒𝑐




Where 5.5 mm/sec is the default speed of the MPPD system and Speed not treated 
tissue is the speed measured by the analysis of the beads speed in the not treated 
tissue. 
The “Tracheal Mucous Velocity” specific for the compound treated tissue was 
calculated using the following equation: 
𝑇𝑟𝑎𝑐ℎ𝑒𝑎𝑙 𝑀𝑢𝑐𝑜𝑢𝑠 𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 = 𝑇𝑟𝑒𝑎𝑡𝑒𝑑 𝑡𝑖𝑠𝑠𝑢𝑒 𝑀𝐶𝐶 ∙ 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
Where the treated tissue MCC measured by the analysis of the beads speed in the 
compound treated tissues.   
After accepted the parameters setting and the run of the analysis, the results were 
plotted and reported in tracheal-bronco clearance (TB Clearance vs time).  
 
5 RESULTS  
5.1 Acute Toxicity Assessment 
In this project a step-wise strategy is proposed in order to increase the rate of success 
in the drug candidate selection phase. Ideally, safety data should be integrated with 
early PK and efficacy indications in order to increase chances to select the candidate 
with the highest safety margin. With this ambitious objective in mind, two in vitro 
cell models were considered: 
 A549 cell line was qualified and proposed as preliminary cell model for 
doses dependent toxicity of selected compound to be tested in the 
SmallAir™ model; 
 SmallAir™ (Epithelix Sàrl) model was qualified and proposed as the final 
model to be used to generate physiological human-relevant data.  
The 3D model SmallAir™ was evaluated as more physiological model for acute 
toxicity assessment both after single treatment of single concentrations and after a 
single dose of a range of concentrations.  
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In the single dose toxicity test three compounds known to be toxic for the lung were 
analysed in order to qualify the SmallAir™ model as possible in vitro model able 
to distinguish toxic and no toxic substances after a single dose exposure: 
1) Dimethylamine Cadmium Chloride (CdCl2)  
2) lipopolysaccharides (LPS),  
3) Transforming growth factor beta (TGF-β)  
 
Cadmium Chloride is a well-known lung toxicant compound. It is a ubiquitous 
environmental pollutant, which can cause severe toxicity in various organs, mainly 
the lung, kidney, liver, bone and genitals. Lung tissue is one of the main targets of 
cadmium toxicity and the respiratory system is affected severely by the inhalation 
of cadmium-contaminated air (Oberdörster, 1992). Shortness of breath, lung edema 
and destruction of mucous membranes as part of cadmium-induced pneumonitis 
have been described (Seidal et al., 1993). Cadmium causes lung damage, pulmonary 
fibrosis, emphysema and inflammation in human and experimental animals. 
Cadmium may also adversely affect the lungs by decreasing the viability or 
modifying the function of individual lung cells (Låg et al., 2002). Epidemiological 
studies and in vitro studies demonstrated that CdCl2 exposure causes the disruption 
of the ALI barrier (Forti et al., 2010).  
LPS is widely employed as pro-inflammatory agent in the induced acute lung injury 
in vivo model (De Souza Xavier Costa et al., 2017). 
The TGF-β plays an important role in normal pulmonary morphogenesis and 
function and in the pathogenesis of lung disease. The effect of TGF-β is regulated 
via a selective pathway of TGF-β synthesis and signaling that involves activation 
of latent TGF-β, specific TGF-β receptors, and intracellular signaling via SMAD 
molecules. TGF-β is involved in normal tissue repair following lung injury. 
However, in a variety of forms of pulmonary pathology, the expression of TGF-β 
is increased. These include chronic lung disease of prematurity as well as several 
forms of acute and chronic adult lung disease. The increase in TGF-β precedes 
abnormalities in lung function and detectable lung pathology, but correlates with 
the severity of the disease. TGF-β plays a key role in mediating fibrotic tissue 
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remodeling by increasing the production and decreasing the degradation of 
connective tissue via several mechanisms (Bartram & Speer, 2004). 
For the dose-related toxicity test a range of concentration of known toxic substances 
have been tested, in order to estimate an EC75, considered as the effective 
concentration which results in 75% of viability of the tissue. These compounds were 
tested on the submerged A549 model, considered as possible model for a 
preliminary screening for the dose concentrations selection, and SmallAir™ as 





Test 1 (single dose acute toxicity, 6 hours of treatment  
After 6 hours treatment with Dimethylamine 0.73 mg/mL a marked decrease of 
viability was observed up to 75.7% ± SD 11.2 of viability in comparison to negative 
control (Figure 31). 
 
Figure 31. Test 1 Acute toxicity results: Viability assessed by the Resazurin test of the SmallAir ™ 
after 6 hours treatment with Dimethylamine 0.73 mg/mL.  The viability is expressed as % 
of mean viability of 2 tissues ± SD treated compared to negative control. The viability of 
tissues treated was 75.7% ± SD 11.2 compared to negative control.  
A decrease in the TEER values, both for the negative control and for 
Dimethylamine treated tissues was observed after 6 hours treatment. No decrease 
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in TEER values was observed for the Dimethylamine treatment versus the negative 
after 6 hours of treatment (Figure 32). 
 
Figure 32. Test 1 TEER Reduction results: Graphical representation of TEER reduction of 
SmallAir™ tissues at T0 and after 6 hours of treatment with Dimethylamine 0.73 mg/mL. 
(mean of 3 tissues ±. SEM). A statistically significant decrease (**: p ≤ 0.01) was 
observed after 6 hours both for negative control and treated tissues. No decrease was 
observed for the tissues treated compared to the negative control. 
 
Test 2 (single dose acute toxicity, 72 hours of treatment  
Tissues treated with CdCl2 showed a significant decrease in the viability (64.7% in 
comparison to negative control). Slight but no significant decrease in the viability 
was observed after the treatment with LPS while a significant slight decrease 
(92.5% in comparison to negative control) after treatment with TGF-β was observed 
(Figure 33). 
Regarding the TEER values, a high variability was observed. However, a marked 
and significant decrease in TEER values was observed after 72 hours of treatment 
with CdCl2, while a slight decrease was observed after TGF-β. No decrease was 




Figure 33. Test 2 Acute toxicity Results: Graphical representation of the viability assessed by the 
Resazurin test of the SmallAir ™ treated with LPS 100 ng/mL, CdCl2 100 µM and TGF-
β 10  ng/mL. The viability is expressed as % of mean viability of 3 tissues ± SEM treated 
compared to negative control. A statistically significant decrease of viability was 
observed for the tissues treated with CdCl2 100 µM and TGF-β 10  ng/mL (*: p ≤ 0.05; 
**: p ≤ 0.01). 
 
 
Figure 34. TEER Reduction Test 2 Results: A. Graphical representation and statistical analysis of 
TEER reduction of SmallAir™ tissues treated with LPS 100 ng/mL, CdCl2 100 µM and 
TGF-β 10 ng/mL. A significant decrease compared to negative control after 72 hours was 
observed for tissues treated with CdCl2 100 µM only. No decrease was observed in any 
other treatment condition (**: p ≤ 0.01).  
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Test 3 (dose-related acute toxicity 
Data obtained in the Test 3 are reported for each test compound in Figure 35 and 
Figure 36 for SmallAir™ and A549 respectively. 
In detail, a high variability intra experiments was observed, mainly for the negative 
control. Despite this variability, a dose related toxicity was observed for H2O2, 
Glycidol and Dimethylamine in both cell models and the EC75 was calculated for 
these compounds (Table 5). No dose related toxicity was observed for Diethylamine 
and no accurate EC75 was calculated  
 
 
Figure 35. Acute toxicity Test 3 in SmallAir™ results: Viability of the SmallAir ™ tissues assessed 
by the Resazurin test after 3 hour of treatment with a dose range concentration of H2O2 
(A), Glycidol (B), Dimethylamine (C) and Diethylamine (D). A dose concentration related 
decrease of viability dose was observed for H2O2 and Glycidol.  A decrease of viability 
at the highest concentration tested only was observed for Dimethylamine and 




Figure 36 Acute toxicity Test 3 in A549 results:  Viability of the A549 cultures  assessed by the 
Resazurin test after 3 hour of treatment with a dose range concentration of H2O2 (A), 
Glycidol (B), Dimethylamine (C) and Diethylamine (D). A dose concentration related 
decrease of viability dose was observed for H2O2, Glycidol and Dimethylamine.  A 
decrease of viability at the highest concentration tested only was observed for 
Diethylamine treatment. 
Table 5. EC75 values calculated for  Glycidol, Dimethylamine and H2O2, for SmallAir™ and A549. 
(GraphPad Prism 8) 
 
The decrease in viability assessed by the Resazurin test was confirmed by the 
morphological observation. As shown in Figure 37, the tissue resulted damaged 
with the loosing of the integrity of the barrier and fluctuant cells. The extent of 
damage observed for each compound treatment correlated with the decrease of 
viability observed, ranging from slight loss of cells to the complete detachment of 
the tissue form the membrane. The image of tissues treated with Glycidol only is 















Figure 37. Morphology appearance of the tissues after 3 hours of treatment with negative control 
(A), Glycidol 1 mg/mL (B) and Glycidol 4 mg/mL (C). At the highest concentration a 
marked decrease of the integrity of the tissues was observed.(inverted microscope model 
Leica DML, 12 MPX f/1.7 Samsung S7 camera with magnification 10X).  
 
The LDH released in the medium after treatment with H2O2, Glycidol, 
Dimethylamine and Diethylamine was assessed using LDH-Glo™ Cytotoxicity 
Assay and the fold increase in comparison to the negative control of each treatment 
is reported in Table 6. No clear dose related increase in the LDH was observed for 









Table 6.  LDH Release measured by LDH-Glo™ Cytotoxicity Assay in the medium after treatment 
with H2O2, Glycidol, Dimethylamine and Diethylamine. No dose related increase in LDH 






Fold Increase ± 
sem 
Tissue 1 




1 1.372±0.059 0.959±0.032 
 
4 0.626±0.020 0.265±0.009 
 
12 1.485±0.068 0.081±0.002 
 Dimethylamine 
0.5 0.996±0.034 0.536±0.015 
 
1 0.911±0.047 0.575±0.020 
 
1.5 1.744±0.073 1.028±0.014 
 Diethylamine 
0.5 1.476±0.015 0.334±0.085 
 
1.5 1.686±0.050 0.736±0.004 
 
3 3.380±0.048 1.096±0.009 
 H₂O₂ 
5 1.264±0.016 0.350±0.037 
15 4.061±0.049 -1.861±0.066 
 
30 1.903±0.004 1.300±0.007 
 
 
The extent of the damage observed in the integrity of the tissues correlated with 
their ability to replicate and recover from the injury. As observed in a preliminary 
test, tissues presenting slight loss of cells were able to recuperate while, when the 
damage was more extensive, tissues showed not to be able to recover. As example, 
the images of tissues treated with Dimethylamine at 0.1, 0.5 and 2.5 mg/mL after 1 
week of recovery period are reported in Figure 38. As can be seen, tissues treated 
with low concentrations showed to recover the loss of cells, appearing similar to 
the negative control, while in the tissue treated with the highest concentration the 
loss of cells was still evident with marked area without cells and fluctuant cells on 





Figure 38. Images of tissue treated  for 6 hours with Dimethylamine at 0.1, 0.5 and 2.5 mg/mL after 
1 week of recovery. Dimethylamine 1.5 mg/mL. Tissues treated with the lower 
concentrations, show to recover the loss of cells and appearing similar to the negative 
control, while in the tissue treated with highest concentration the loss of cells is still 
evident with marked area without cells and fluctuant cells on the surface (inverted 
microscope model Leica DML, 12 MPX f/1.7 Samsung S7 camera with magnification 
10X).  
However, the similarity in the appearance with the negative control was not 
confirmed by the viability (< 75 % compared to negative control) measured by the 
Resazurin test (Figure 39). These results could be explained by the possible 
mechanism of action of the toxic compound tested not only as irritant and corrosive 






Figure 39. Graphical representation of the viability of SmallAir™ tissues  assessed by the Resazurin 
test immediately after treatment with Dimethylamine 0.1, 0.2 and 2.5 mg/mL (A) and after 
1 week of recovery period (B). After 1 week of recovery period all tissues showed a 
decrease in the viability compared to the values measured immediately after the 
treatment.  
 
In order to confirm the ability of the tissue to recover the tissue integrity by its 
replicative capability, one tissue was damaged on purpose and left to recovery. 
After 24 hours cells replicated and were able to recover the damage and to 







Figure 40. Image of tissue mechanically damaged (A) and the recovery of the integrity of the tissue 
after 24 hours (B) (inverted microscope model Leica DML, 12 MPX f/1.7 Samsung S7 
camera with magnification 10X). 
 
The results of the three test indicate that the Resaruin viability test was able to 
identify toxic and irritant compounds applied on SmallAir™ model. The TEER 
measurement, while the TEER measurement was considered not suitable as toxic 
end point. 
 
5.1.1 Histology Observation 
The tissue organization of SmallAir™ cells were evaluated by histological staining.  
The histoogical evaluation was conducted only in the single dose toxicity test after 
72 hours of treatment with LPS, TGF-β and CdCl2. In the not treated tissues a 
typical and well preserved respiratory epithelium characterized by AT-I and AT-II 
normally represented in number and shape was observed (Error! Reference source 
ot found.). In tissues treated with LPS minimal to slight increase in apoptotic cells 
was evident. Although in general tissue appeared well preserved and organized, 
focal areas of cellular disorganization were also present (Error! Reference source 
ot found.). In TGF-β treated tissue, a mild to moderate increase in apoptotic cells 
associated with necrotic cell characterized by nuclear shrinking and cellular debris. 
In addition an alteration of tissue architecture was evident (Error! Reference 
ource not found.). Finally, CdCl2 treatment caused a severe tissue disorganization, 
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characterized by cellular hypertrophy and hyperplasia and associated with diffused 








Figure 41. Histology examination of SmallAir™.  1. Not treated tissues with a typical and well 
preserved respiratory epithelium characterized by AT-I (a) and AT-II (b) normally 
represented in number and shape. 2. Tissue treated with LPS LPS 100 ng/mL for 72 
hours. A. A slight increase in apoptotic cells was observed (a). B. Focal areas of cellular 
disorganization. 3. Tissue treated with TGF-β 10 ng/mL for 72 hours. A. A mild to 
moderate increase in apoptotic cells (a). B. Apoptotic cells associated with necrotic cell 
characterized by nuclear shrinking and cellular debris (b). C. Apoptotic and necrotic 
cells and alteration of tissues architecture. Focal areas of cellular disorganization. 4, 
Tissue treated with CdCl2 100µM for 72 hours. A. severe tissue disorganization, 
characterized by cellular hypertrophy and hyperplasia and associated with diffused 
apoptotic (a) and necrotic (b) cells. B. Detail of the tissue architecture disorganization. 
C. Necrotic area and detachment from the basal lamina was observed.  D. Detail of 
necrotic area with necrotic cells characterized by nuclear shrinking and cellular debris 
(inverted microscope model Leica DML, 12 MPX f/1.7 Samsung S7 camera with 
magnification 20X).  
These results confirm that irritant and toxic compound on SmallAir™ model induce 
a tissue disorganization and an increase in apoptotic and necrotic cells.  
5.2 Transport Evaluation (Permeability) 
The SmallAir™ 3D cell model was applied in order to evaluate the transport of 
selected compounds through lung tissues. Preliminary tests on transport of aerosol 
compounds produced by e-cigarette and transport of drug compound as powder 
formulation have been conducted.  
Different cell lines are commonly used for in vitro permeability studies, but none 
of them is known to correctly represent the lung epithelium. The Caco-2 cells model 
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is considered the standard model and it is used for the Biopharmaceutics 
Classification System (BCS) by FDA (Food and Drug Administration)(Smetanová 
et al., 2011), but little is  reported in literature about their translational contribution 
to the study of  inhaled drugs.  
The commercial 3D respiratory cells model SmallAir™ was evaluated as 
representative of a physiological model for permeability studies of new formulation 
of inhaled compounds. A set of commercially available inhaled compounds were 
tested as liquid formulation in SmallAir™ and permeability data obtained were 
compared with data obtained in the standard  Caco2 cells model.   
Compounds selected for the permeability assessment as liquid formulation were:  
- Salbutamol: it is a β2-adenoreceptor agonist used in the treatment of asthma, 
COPD and bronchitis that acts relaxing the smooth muscles of all airways 
resulting in a bronchodilation (www.drugbank.ca). The Salbutamol was 
assessed as active pharmaceutical ingredient form (API) and as aerosol 
formulation (Broncovaleas®). 
- Budesonide: they are corticosteroids used in the treatment of asthma and 
some kind of rhinitis (as well as some skin diseases) (www.drugbank.ca). 
Budesonide was used both as API and as suspension for nebulization 
(Budesonide Aircort®) while FP was used as API. 
- Theophylline: it is a methylxanthine indicated for asthma, bronchospasm, 
and COPD treatment.  
- Tiotropium bromide: it is an antimuscarinic bronchodilator used in the 
treatment of COPD and asthma commercially available as Spiriva Respimat 
(Boehringer Ingelheim Pharmaceuticals, Inc.) in the form of solution per 
inhalation with its inhaler (www.drugbank.ca).  
- Digoxin: it is a well-known P-gp substrate and it was tested in order to 
assess the presence of the P-gp transporter in the SmallAir™ cells. 
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The commercial device CULTEX® RFS Compact (Cultex Laboratories GmbH, 
Hannover, Germany) has been evaluated as exposure device for nebulized drug 
formulation (L.Pomari 2019) and for e-smoke exposure. 
Additionally, an experiment was performed to evaluate the permeability of a 
compound as powder formulation.  For the treatment with the powder form of the 
compound tested,a modification of the Next Generation Impactor (NGI) was 
implemented. The permeability of the deposited powder was compared with data 
obtained after treatment with liquid formulation.  
5.2.1 Permeability studies in SmallAir™ - liquid treatment  
The permeability data obtained for each compound analyzed in SmallAir™ are 
showed in Table 7. The results are expressed as the mean of the permeability (Papp) 
values of each sample ± SD, while the Efflux Ratio is expressed as mean of each 
experiment ± SD. 
Compound A to B 
(nm/sec) 






Salbutamol 2.92 ± 
2.12 
12 5.70 ± 
4.63 
9 2.47 ± 
1.98 
Efflux 








7 11.3 ± 9.o 7 3.81 ± 
1.08 
Efflux 




Table 7. Permeability results through SmallAir™. Permeability results of Salbutamol, Budesonide, 
Tiotropium Bromide and Digoxin in direction A to B and B to A in nm/sec and Efflux 
Ratio is expressed as mean values of replicate (N) ± SD.   
 
In detail, Salbutamol and Tiotropium bromide showed a higher B to A permeability, 
resulting to be low permeability compounds and therefore good candidates for 
efflux transporters’ substrate. Budesonide did not show a net transport and therefore 
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showed to be a high permeability compound. Digoxine did not show a net transport 
but with a medium permeability in both directions.   
Permeability observed in SmallAir™ cells showed to be comparable with data 
obtained in Caco2 (L. Pomari, 2019). However, a couple of differences were 
observed. First of all, B to A permeability of Tiotropium bromide and A to B 
permeability of Digoxin in SmallAir™ were statistical significant higher in 
comparison to Caco2 model (Figure 42). 
 
Figure 42. Permeability expressed as Papp (nm/sec) of Tiotropium (A) and Digoxin (B) in 
SmallAir™ and Caco2. A higher B to A permeability of Tiotropium bromide and A to B 
permeability of Digoxin was observed in SmallAir™ compared to Caco2 test system Data 
are expressed as Mean ± SD with statistically significant increase (+: p<0.05, ++: 
p<0.01). Taken from L.Pomari, 2019.  
 
Secondly, comparing the ER obtained in SmallAir™ and Caco2 cells, Salbutamol 
showed to diffuse passively in Caco2 while seems to have an efflux in SmallAir™ 
(even if the high variability observed in SmallAir™ did not allow to observe a 
statistically significant difference). Tiotropium bromide showed efflux only in 
SmallAir™. Budesonide did not show an efflux in both model. At last Digoxin, 
which is the reference compound as P-gp substrate for Caco-2 did not show any 






Figure 43. Efflux ratio in SmallAir™ vs Caco2, with limit for efflux consideration set at 2 for 
Salbutamol, Budesonide, Tiotropium bromide and Digoxin. Data are expressed as mean 
for Caco2 and as mean ± SD with statistically significant increase/decrease (+/-: p<005; 
++/--: p<0.01. Taken from L.Pomari, 2019. 
 
Data showed a difference in Tiotropium bromide and Digoxin’s efflux ratio. In 
particular, Digoxin, a well-known P-gp substrate, showed permeability values in 
the two directions A to B and B similar to each other. This observation should be 
due to a less abundant expression of P-gp in SmallAir™ or it might be expressed as 
different isoforme with different specificity for these compound.   
These results indicate that SmallAir™ model should express specific lung 
transporter and better represent the in vivo situation.   
 
5.2.2 Permeability studies in SmallAir™ - aerosol treatment 
CULTEX® was used for the treatment of SmallAir™ tissues with Broncovaleas® 
and Budesonide Aircort®, butno reliable data were obtained. In particular, when 
the CULTEX® was connected to a mixing chamber to combine the aerosol with 
regular air, the aerosol condensation on the inner surfaces of the mixer chamber 
was observed e no aerosol was able to reach the tissues. For the following 
experiment, the nebulizer was then connected directly to the CULTEX® and in 
order to avoid tissues damage different time of exposure have been tested. 
93 
 
However, permeability results obtained were considered not reliable, showing an 
unreasonably high values probably due to the high fluid pressure that could 
facilitate the permeability of the drug through the monolayer. 
In the permeability assessment of nicotine after e-smoke exposure, results of TEER 
measurement pre-treatment and post-treatment showed a high variability 
inter-tissues. However, all values were >200Ω*cm2, indicating no loss in the 




Figure 44. TEER values, expressed as Ω*cm2, measured pre- and post-treatment with e-smoke 















The results obtained in the LY assay, also confirmed the integrity of the tissues. In 
particular in Test 1 % of rejection for all tissues were 100 % where in Test 2 tissue 
showed values of % of rejection ranging between 97.3 % and 98.4%. 
The viability assessment of the tissues, in the Test 1 was 90.52% and 84.67% 
(average of two tissues) immediately after vehicle and e-liquid treatment 
respectively. In the Test 2, the viability of the tissues was 97.99% and 78.09% 
(average of two tissues) immediately after vehicle and e-liquid treatment 
respectively. Data are graphically showed in Figure 45. 
 
 
Figure 45. Graphical representation of viability of SmallAir™ measured after treatment with e-
smoke produced by two different devices (A. Test 1 and B. Test 2). In both test, viability 
of tissues treated with vehicle and with e-liquid containing nicotine was above 80% 
indicating viability of the tissues. In test 2 the positive control showed a negative viability 
since due to technical problem the H202 remained in contact with the tissue for longer 





Nicotine concentration measured for each device is reported in Table 8. Similar 
nicotine concentrations were measured in the samples obtained from the well 
without tissue and in the samples from the well with tissues. These results, along 
with the integrity of the tissues confirmed by TEER and LY values, suggest that all 
the nicotine has been transported through the tissues. Differences observed between 
the two commercial e-cigarettes tested in Test 1 and Test 2 should be due to 





Table 8.  Nicotine concentrations measured in the medium after e-liquid treatment produced by 
two different devices (A and B respectively). Similar nicotine concentrations were 
observed in samples collected from wells without tissue and with tissues indicating that 
all the nicotine applied passed through the tissues.  Variability observed between the two 
tests should be due different mechanism of action of the two devices evaluated. 
 
Time point 2 min Time point 5 min
No Tissue 3947.89 3943.75
Tissue 1 5523.31 5752.8
Tissue 2 2904.71 3129.06
Average 4125.30 4275.20
SD 1318.28 1342.91
Nicotine Concentration ng/mL (Test 1)
2 min 5 min
No Tissue 1649.66 1383.02
Tissue 1 1358.37 1470.72
Tissue 2 NS 935.44
No Tissue 378.43 367.75
Tissue 1 368.23 397.34
Tissue 2 213.26 212.86
Average 793.59 794.52
SD 659.91 548.02
NS = no sample due to technica l  i s sue













5.2.3 Permeability studies in SmallAir™ - powder treatment 
The reliability of the use of the NGI modified as device to treat tissue transwells, 
was confirmed by the Leak Test that showed values below 100Pa/s. 
Furthermore in the preliminary test conducted to confirm that the same amount of 
compound was deposited in each well comparable peak area (expressed as µV*sec) 
were obtained, considering the analytical variability (Table 9).  
TEST 1 TEST 2 
Sample 1 3396 µV*sec Sample 1 2848 µV*sec 
Sample 2 2591 µV*sec Sample 2 4102 µV*sec 
Sample 3 2239 µV*sec, Sample 3 6201 µV*sec 
Table 9. Area peak (expressed as µV*sec) of Tiotropium Bromide dry poweresults obtained in 
the preliminary test with NGI modified. Comparable peak area were obtained, 
considering the analytical variability. 
 
In the final test, the TEER of the two tissues treated with Tiotropium Bromide dry 
power was measured pre and post treatment and no effect on TEER was observed 
indicating the integrity of the tissue.  Value measured are showed in Table 10. 
 
Table 10.  TEER values (Ω·cm2) measured pre and post treatment with aerosol of Tiotropium 
bromide, using the Next Generation Impactor. 
 
Despite the TEER values, the microscopic observation (Figure 46) showed the 
presence of some air bubbles in one tissue that resulted in the detachment of tissue 












Figure 46. Image of the tissues treated with aerosol of Tiotropium bromide by the Next Generation 
Impactor. Evident air bubbles have been observed, resulting in the final detachment and 
death of the tissues (inverted microscope model Leica DML, 12 MPX f/1.7 Samsung S7 
camera with magnification 10X). 
   
5.3 Inflammatory mediators assessment 
The following inflammatory mediators were selected in the analyses: 
- pSMAD2 
- Cytokines and pro-inflammatory mediators: IL-6, RANTES, IP-10, 




5.3.1 pSMAD2 assessment 
One of the major mediators of extracellular matrix (ECM) remodeling either in 
physiological (such as wound healing) or pathological conditions (as in pulmonary 
fibrosis) is the cytokine TGF-β1. TGF-β1 belongs to the TGF-β superfamily, and 
as the highly homologous isoforms TGF-β2 and TGF-β3, is usually present in the 
ECM in a latent form. Following TGF-β1 activation (e.g. proteolytic cleavage, 
interaction with integrins or pH changes), active TGF-β1 is free to bind its receptors 
at the cell surface. All the members of TGF-β superfamily signal via heteromeric 
complexes of two related transmembrane type I and type II serine/threonine kinase 
receptors, known as ALK5. The activation of ALK5 leads to the propagation of 
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signaling by the SMAD-dependent pathway, through ALK5-mediated 
phosphorylation of SMAD2 and SMAD3, which in turns regulate transcription of 
target genes (Zi et al., 2014).  
TGF-β has been widely evaluated for its crucial role in the development of 
pulmonary fibrosis and airway remodeling during the late phases of chronic lung 
injury therefore in this project the SMAD2 phosphorylation was assessed in the 
SmallAir™, in order to evaluate the potential of this test system as more 
physiological in vitro pulmonary fibrosis model. Indeed, understanding the precise 
molecular mechanism that lead to ECM remodelling could help in the identification 
of novel therapeutic targets for fibrosis in the lung. 
 
5.3.2 Cytokines release, ROS and LDH release 
In vivo pulmonary toxicity is characterized by an initiating event such as bacterial 
or viral infection or chemical insult that leads to the activation of the inflammatory 
response. This initial activation induces the production of proinflammatory 
cytokines, such as interleukin 1-alpha (IL-1α), interleukin 6 (IL-6), interleukin 8 
(IL-8), tumor necrosis factor alpha (TNF-a), and TGF-β), that induce neutrophil 
activation and migration to the alveolar space. Activated neutrophils continue the 
immunological initiation process by induction of reactive oxygen species (ROS), 
cytokines and chemokines (Willoughby J.A., 2015). A preliminary experiment was 
conducted in order to evaluate the SmallAir™ model as possible in vitro model for 
inflammatory end points assessment such as cytokines secretion, lactate 
dehydrogenase (LDH) release and ROS. For this purpose, the effect of the 
bleomycin treatment was assessed.  
The most common animal model of pulmonary fibrosis is the bleomycin model in 
rodent. Over the years, numerous agents have been tested in this model. The 
translation of these results into clinical practice has not been accomplished yet, 
therefore  the evaluation of alternative and/ or complementary models which better 
reflect human idiopathic pulmonary fibrosis (IPF) is desired (Moeller et al., 2008). 
Bleomycin is a chemotherapeutic antibiotic, produced by the bacterium 
“Streptomyces verticillus” and one of the major adverse drug effects of bleomycin 
in human cancer therapy is the pulmonary fibrosis (Hare, 1998; Karam et al., 1995). 
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The mechanism of bleomycin toxicity is unclear and likely multifactorial. Oxidative 
damage, release of inflammatory cytokines, a deficiency of the bleomycin 
hydroxylase enzyme in the lungs and genetic predisposition have been described 
(Ge et al., 2018). An overproduction of reactive oxygen species can lead to an 
inflammatory response causing pulmonary toxicity, activation of fibroblasts and 
subsequent fibrosis. The initial elevation of pro-inflammatory cytokines is followed 
by increased expression of pro-fibrotic markers (transforming growth factor-β1, 
fibronectin, procollagen-1) (Moeller et al., 2008).   
In order to evaluate the SmallAir™ cells as possible in vitro model for pulmonary 
fibrosis the effect of bleomycin treatment was assessed by the measurement of 
different end points such as cytokines and LDH, ROS production and viability. 
  
5.3.3  pSMAD2 analysis   
Results obtained for the pSMAD2 assessment are reported in the Figure 47Figure 
47. In detail, pSMAD2/tSMAD2 ratio was significantly increased by TGF-β 
























































Figure 47. Results of pSMAD2 quantificiation in SmallAir™ after TGF-β treatment and statistical 
analysis (Meso Scale Discovery’s Assay). A. pSMAD2 concentration (expressed as raw 
data) after 1 and 3 hours of treatment. B tSMAD2 concentration (expressed as raw data) 
after 1 and 3 hours of treatment. C. pSMAD2/tSMAD2 ratio after 1 and 3 hours of 
treatment.   
 
5.3.4 Cytokines, LDH release and ROS evaluation 
Cytokines release. Results obtained in the measurement of cytokines and pro-
inflammatory mediatory release after Bleomycin treatment are presented in Figure 
48. 
Eight different cytokines and pro-inflammatory mediators were analysed: IL-6, 
RANTES, IP-10, ETXN, IL-4, MIP-1β, IL-8 and GRO. 
IL-6 was not significantly modulated by Bleomycin treatment. RANTES and IP-10 
showed a decreasing trend after Bleomycin treatment compared to negative control. 
Etxn, IL-4 and MIP-1β seems to be poorly secreted by the tissue, showing levels 
below the determination limit. While IL-8 and GRO levels showed to be out of 


































Figure 48. Cytokines measurement in the medium after Bleomycin treatment at 10, 30 and 
100 µM for 24 and 72 hours (Luminex bead-based Multiplex Assay). 
 
Viability of SmallAir™ tissues was measured in presence of increased amounts of 
Bleomycin. and results are presented in the Figure 49. No effect on viability was 
observed in SmallAir™ tissues after 48 hours of treatment with Bleomycin at 10, 




Figure 49. Viability of SmallAir™ tissues expressed as % versus negative control after 48 hours of 
treatment with Bleomycin at 10, 20 and 100 µM. 
 
These results were confirmed by the microscopical observation. As showed in 
Figure 50 no damage to the integrity of tissues was observed.  
LDH release. Samples obtained from the medium of SmallAir™ cultures treated 
with Bleomycin at concentration of 10, 30 and 100 µM were analyzed with a 
bioluminescence method (LDH-Glo™ Cytotoxicity Assay). Results are showed in 
Table 11. A high variability between the samples were observed. No increase was 
observed after 24 hours of treatment except for the Tissue 3 at 100 µM. A slight 
increase was observed after 48 hours for all condition tested, but no dose related 
trend was observed except for Tissue 3 at 100 µM. The LDH positive control was 
















Figure 50. Images of SmallAir™ tissues after 48 hours of treatment with Belomycin at 10, 30 and 
100 µM (inverted microscope model Leica DML, 12 MPX f/1.7 Samsung S7 camera 
with magnification 10X). 
Table 11. LDH Release measured by  LDH-Glo™ Cytotoxicity Assay in the medium following 
Bleomycin 10, 30 and 100 µM treatment after 24 and 48 hours. An increase in the LDH 












0.71 1.21 1.22 
30 µM 0.71 1.05 1.15 
100 µM 0.65 0.91 1.76 
10 µM 
48 hr 
2.58 1.24 1.04 
30 µM 2.53 1.11 1.55 




ROS measurement. Samples obtained from the medium of SmallAir™ cultures 
treated with Bleomycin at concentration of 10, 30 and 100 µM were analysed with 
the luminiscence method ROS-Glo™ H2O2 Assay. The method was not able to 
measure any amount of ROS in the samples and all samples resulted to be under the 
detection limit indicating that the method used should be not suitable for the ROS 
measurement in SmallAir™ model. 
 
5.4 Muco-ciliary Clearance Assessment 
Different drugs can be administered in order to alleviate respiratory disorders, such 
as dyspnea and bronchospasm. Some of these drugs, however, are claimed to 
influence the (MCC). Since MCC plays an important role as defense mechanism, 
the influence on MCC of drugs administered to patients with respiratory disorders 
must be evaluated. 
The role of airway clearance in inhaled drug therapy is complex. The knowledge of 
the influence of a specific drug on mucus clearance may lead to a better therapeutic 
use of such medication (Houtmeyers et al., 1999).  
Furthermore, MCC is reported to be impaired in certain diseases, such as cystic 
fibrosis (CF), chronic obstructive pulmonary disease (COPD), primary ciliary 
dyskinesia (PCD), chronic rhinosinusitis (CRS), and asthma (Joo et al., 2016). 
Optimal airway muco-ciliary clearance depends upon the speed and effectiveness 
of ciliary beating, the rheological properties of the mucus, and structurally intact 
airways. 
In this project the SmallAir™ model was investigated as a possible in vitro model 
for the assessment of MCC in response to exposure to different compounds: 
 agonists Forskolin  and Carbachol  
 ion transport inhibitors CFTRInh-172  
 a set of commercially available inhaled compounds, ipertonic solution 
(NaCl 3%) and LPS  
 
Forskolin is a member of the diterpene family and activates the Cystic fibrosis 
transmembrane conductance regulator (CFTR) chloride channel by raising the 
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amount of intracellular cyclic AMP, leading to fluid secretion. The CFTRInh-172 
is an inhibitors of CFTR chloride channel and it is used as tools to investigate the 
role and function of CFTR conductance in cystic fibrosis research. (Melis et al., 
2014). Joo N.S et al. observed in an ex vivo ferret trachea model that CFTR 
inhibitors modestly depressed MCCV stimulated by [cAMP]i –elevating agents, but 
not basal MCCV nor that stimulated by [Ca2+]–elevating agents (Joo et al., 2016).  
Carbachol, a synthetic choline, acts as nicotinic acetylcholine receptor agonist and 
it showed to increase the MCC by increasing [Ca2+] (Joo et al., 2016).  
The effect of inhaled compound Budesonide, Salbutamol, Tiotropium bromide, 
Fluticasone and Theophylline on MCC in SmallAir™ was evaluated and results 
were used as input data for a in silico simulation with the MPPD model, in order to 
assess the impact of the MCC variation in the excretion of an inhaled compound. 
Airways contaminants like lyposaccharide (LPS) activate a specific toll like 
receptors (TLR4) of the immune system that produce an inflammatory response 
associated to the production of cytokines by the airway epithelium. Test conducted 
on Primary cultures of mouse (Balbc) tracheal epithelium showed that LPS induces 
an increase in CBF in a dose response manner by increasing the release of ATP (D. 
V. Carreno et al., 2013). 
The ipertonic solution (NaCl 3%) was assessed to confirm the block effect reported 
in literature (Schipper & Verhoef, J.C. & Merkus, 1991). 
 
5.4.1 Results of Automatic and Manual methods evaluation. 
The number of frames captured by the automatic analysis (Mosaic- Particle Tracker 
2D/3D plugins), for both muco-ciliary Test 1 and Test 2 were analysed. Since 
reproducible results were obtained with both test, only one condition (negative 
control) is reported in Figure 51. In detail, the results showed that in each conditions 
analysed a high percentage of trajectories are constituted by few frames (lower 
than10) or by the maximum of 50 frames. Observing the video of trajectories 
captured, the system showed to lose the tracking of many beads during the path 
making the analysis not reliable. Therefore for the following analysis of the speed 




Figure 51. Analysis of the distribution of frames number for the trajectories captured by Mosaic- 
Particle Tracker 2D/3D plugins. 
 
The effect on the MCC of the treatment with CFTRInh-172 20 µM and FRSK 3 µM 
evaluated by automatic and manual method are reported in Figure 52 and Figure 
53 respectively. Both in automatic and in manual analysis the treatment with CFTR 
showed to decrease significantly the MCC in comparison to the not treated tissue.  
The FRSK treatment following the CFTR treatment showed to decrease the MCC 
in the automatic analysis while to increase the MCC in the manual analysis. Only 






Figure 52. Muco-ciliary results expressed as beads speed (mm/sec) in  SmallAir™ after treatment 
with CFTRInh172 at T0, T10 and T20 followed by treatment with FRSK 3 µM at T0, T10 
and T20 obtained by automatic analysis. CFTR treatment showed to decrease the MCC 
compared to the not treated tissue at T0 and T10. A decrease of MCC after FRSK 
treatment following the CFTR treatment was observed at T20. Statistical significance 
difference of each treatment versus not treated tissues is represented by green * (*: p< 
0.05; **: P<0.001); the statistical significance difference of FRSK treatment versus the 
last time point of CFTR treatment is represented by red * (*: p< 0.05)..  
 
Figure 53.  Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after treatment 
with CFTRInh172 20 µM at T0, T10 and T20 followed by treatment with FRSK 3 µM 
at T0, T10 and T20 obtained by manual analysis.  CFTR treatment showed to decrease 
the MCC compared to the not treated tissue at T10 and T20. An increase of MCC after 
FRSK treatment was observed both in comparison to the not treated tissues at T10 and 
T20 and in comparison to the CFTR treatment at each time point. Statistical 
significance difference of each treatment versus not treated tissues is represented by 
green * (**: P<0.001); the statistical significance of difference FRSK treatment versus 
the last time point of CFTR treatment is represented by red * (**: P<0.001). 
Treatment:
CFTR 20 µM












The comparison of the automatic and manual method in the analysis of the effect 
on the MCC of the treatment with FRSK 3 µM followed by CFTR is reported in 
Figure 54 and Figure 55 respectively. The CFTR seemed to increase the MCC in 
comparison to the not treated tissue in the automatic analysis while it showed to 
decrease the MCC in the manual analysis, confirming microscopical analysis. No 
increase in the in the MCC after FRSK treatment was observed both in automatic 
and in manual analysis. 
 
Figure 54. Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after treatment 
with FRSK 3µM at T0, T10 and T20 followed by treatment with CFTRInh172 20 µM at 
T0, T10 and T20 obtained by automatic analysis. CFTR treatment showed to increase the 
MCC in comparison to the not treated tissue at T10 and at each time point in comparison 
to FRSK treatment.  Statistical significance of difference of each treatment versus not 
treated tissues) is represented by green * (*: p< 0.05); the statistical significance 
difference of CFTR treatment versus the last time point of FRSK treatment is represented 
by red * (*: p< 0.05; **: P<0.001).  
Treatment:
FRSK 3 µM 








Figure 55. Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after treatment 
with FRSK 3µM at T0, T10 and T20 followed by treatment with CFTRInh172 20 µM at 
T0, T10 and T20 obtained by manual analysis. CFTR treatment showed to decrease the 
MCC in comparison to the not treated tissue at each time point and at T10 only in 
comparison to FRSK treatment.  Statistical significance of difference of each treatment 
versus not treated tissues (negative control) is represented by green * (**: P<0.001); the 
statistical significance difference of CFTR treatment versus the last time point of FRSK 
treatment is represented by red * (**: P<0.001)..  
 
In conclusion, the comparison between the automatic and manual method for the 
analysis of videos suggested that the manual method better represent the effect on 
beads speed observed by microscopical evaluation. Therefore, the manual method 
was choose as more appropriate method to be applied for the evaluation of the rest 
of videos. 
5.4.2 Effect of agonists and inhibitor on MCC  
Experiments to evaluate the effect of agonist Forskolin at 3 µM and 10 µM followed 
by inhibitor CFTR and of the inhibitor followed by Forskolin on MCC expressed 
as beads speed (mm/sec) were conducted. In all experiments treatment with 
Forskolin tested at 3 µM and 10 µM showed to increase the MCC both in 
comparison to the negative control and after CFTR inhibitor treatment as showed 
in Figure 56 and Figure 57 respectively. The CFTR showed to decrease the MCC 
both in comparison to the negative control and in comparison to FRSK treatment 
as showed in Figure 58 and Figure 59.  
Treatment:
FRSK 3 µM 








Figure 56. Muco-ciliary results expressed as beads speed (mm/sec) in  SmallAir™  after treatment 
with CFTRInh172 20 µM at T0, T10 and T20 followed by treatment with FRSK 3 µM at 
T0, T10 and T20. CFTR treatment showed to decrease the MCC in comparison to the not 
treated tissue at T10 and T20. An increase in the MCC was observed after treatment with 
FRSK both in comparison to the not treated tissue at T10 and T20 and in comparison to 
CFTR treatment at each time point. Statistical significance of difference of each treatment 
versus not treated tissues is represented by green * (**: P<0.001); the statistical 
significance of difference of FRSK treatment versus the last time point of CFTR treatment 
is represented by red * (*: p< 0.05; **: P<0.001). 
 
Figure 57. Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after the treatment 
with CFTRInh172 20 µM at T0, T10 and T20 followed by treatment with FRSK 10 µM at 
T0, T10 and T20. CFTR treatment showed to decrease the MCC in comparison to the not 
treated tissue at each time point. An increase in the MCC was observed after treatment 
with FRSK both in comparison to the not treated and in comparison to CFTR treatment 
at each time point. Statistical significance of difference of each treatment versus not 
treated tissues (negative control) is represented by green * (**: P<0.001); the statistical 
significance of difference of FRSK treatment versus the last time point of CFTR treatment 
is represented by red * (*: p< 0.05; **: P<0.001). 
Treatment:
CFTR 20 µM




















Figure 58. Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after treatment 
with FRSK 3µM at T0, T10 and T20 followed by treatment with CFTRInh172 20 µM at 
T0, T10 and T20. FRSK treatment increased the MCC at T10 and T20. CFTR showed to 
decrease the MCC in comparison to the not treated tissue at T0 and T20 and at each time 
point in comparison to FRSK treatment.  Statistical significance of difference of each 
treatment versus not treated tissues (negative control) is represented by green * (*: p< 
0.05**: P<0.001); the statistical significance difference of CFTR treatment versus the 
last time point of FRSK treatment is represented by red * (**: P<0.001 
 
Figure 59. Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after the treatment 
with FRSK 10 µM at T0, T10 and T20 followed by treatment with CFTRInh172 20 µM at 
T0, T10 and T20. FRSK treatment increased the MCC in comparison to the negative 
control at each time point. CFTR treatment showed to decrease the MCC in comparison 
to the not treated tissue at T10 and T20 and at each time point in comparison to FRSK 
treatment. Statistical significance of difference of each treatment versus not treated 
tissues (negative control) is represented by green * (*: p< 0.05**: P<0.001); the 
statistical significance difference of CFTR treatment versus the last time point of FRSK 







FRSK 3 µM 
CFTR 20 µM post FRSK
Treatment:
FRSK 10 µM 







Some differences were observed between the experiments in terms of the time point 
in which the beads speed was affected. This could be due to physiological difference 
between tissues derived from different donor and the maintaining time of tissues in 
culture.  
No reproducible results were obtained in the evaluation of MCC after Carbachol 
treatment. In preliminary experiment, an increase in the beads speed was observed 
(Figure 60). While, when tested at different time point and followed by the 
inhibitor, the effect on beads speed was not confirmed (Figure 61). 
 
Figure 60. Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after the treatment 






Figure 61. Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after the treatment 
with Carbacho 10 µM at T0, T10 and T20 followed by treatment with CFTRInh172 20 µM 
at T0, T10 and T20. No increase in MCC was observed after treatment with Carbachol 
as should be expected. Conflicting result were observed after CFTR treatment showing a 
decrease and then an increased the MCC at T0 and T20 respectively. Statistical 
significance of difference of each treatment versus not treated tissues (negative control) 
is represented by green * (**: P<0.001); the statistical significance difference of CFTR 
treatment versus the last time point of Carbachol treatment is represented by red * (**: 
P<0.001 
 
5.4.3 Effect of drug compounds on MCC  
The MCC clearance in terms of beads speed was significantly increased by the 
treatment with Budesonide 10 µM at T20 and T40 (Figure 62), Salbutamol 10 µM 
at T0 and T40 (Figure 63) and Tiotropium bromide 10 µM at T20 and T40 (Figure 
64). While, a significant decrease in the MCC was observed after Theophylline 
10 µM treatment at T10 and T40 (Figure 65).  A not significant effect after the 















Figure 62. Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after treatment 
with Budesonide 10 µM at T0, T10, T20 and T40. A significant increase in the MCC was 
observed at T20 and T40 in comparison to the negative control. Statistical significance 
is represented by red * (**: P<0.001).  
 
 
Figure 63.  Muco-ciliary results expressed as beads speed (mm/sec) after SmallAir™ treatment with 
Salbutamol 10 µM at T0, T10, T20 and T40. A significant increase in the MCC was 
observed at T0 and T40 in comparison to the negative control. Statistical significance is 








Figure 64. Muco-ciliary results expressed as beads speed (mm/sec) after SmallAir™ treatment 
with Tiotropium 10 µM at T0, T10, T20 and T40. A significant increase in the MCC was 
observed at T20 and T40 in comparison to the negative control. Statistical significance 




Figure 65. Muco-ciliary results expressed as beads speed (mm/sec) after SmallAir™ treatment 
with Theophylline 10 µM at T0, T10, T20 and T40. A significant decrease in the MCC 
was observed at T10 and T40 in comparison to the negative control. Statistical 








Figure 66. Muco-ciliary results expressed as beads speed (mm/sec) after treatment with 
Fluticasone 10 µM at T0, T10 and T20.  A slight but not significant decrease in the 
MCC was observed in comparison to the negative control..  
  
A marked increase on MCC was observed after LPS 1 mg/mL treatment (Figure 
67). Lower concentrations of LPS (100 ng/mL and 1 µg/mL) were tested and they 
showed not to affect the MCC even after a longer time of exposure (Figure 68 and 
Figure 69).  
 
Figure 67 Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after treatment 
with LPS 1 mg at T0. A significant increase in the MCC was observed. Statistical 






Figure 68. Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after treatment 




Figure 69. Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after treatment 
with LPS 1 µg at T0 and T10. No effect was observed.  
 
Results obtained after Saline 3% (ipertonic solution) showed a marked decrease in 




Figure 70. Muco-ciliary results expressed as beads speed (mm/sec) in SmallAir™ after treatment 
with Saline 3% at T0 and T10. After 10 minutes a complete stop in the beads movement 
was observed. 
In addition Budesonide, Salbutamol and LPS treatment in SmallAir™ showed to 
synchronize the cilia beating moving all the beads in the same direction and 
showing a swirling movement. The vectors representing the beads paths are 
















Figure 71. Direction of the beads represented by vectors (ImageJ- PIV Plugin).  
A. Budesonide treatment: 1. No treated tissue. Casual directions of the beads trajectory 
was observed. 2. Tissue treated with Budesonide 10 µM. A synchronization of the 
trajectories was observed with the most of beads moving in the same direction. 3. Tissue 
treated with Budesonide 10 µM. Beads showed a swirling movement.  
B. Salbutamol treatment: 1. No treated tissue. Casual directions of the beads trajectory 
was observed. 2. Tissue treated with Salbutamol 10 µM. A synchronization of the 
trajectories was observed with the most of beads moving in the same direction. 3.  Tissue 
treated with Budesonide 10 µM. Beads showed a swirling movement. C.LPS treatment: 
1. No treated tissue. Casual directions of the beads trajectory was observed. 2. Tissue 
treated with LPS 1 mg/mL. A synchronization of the trajectories was observed with 
showing a swirling movement. 
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5.4.4 MPPD simulation  
The Multiple Path Particle Dosimetry (MPPD) model was considered to evaluate 
the potential of integration of MCC information with in silico methods.  
This model takes into account the lung asymmetry branching pattern and path 
variation resulting in more realistic determination of average deposition fractions 
(Fröhlich et al., 2016).  
The MPPD model calculates the deposition and clearance of monodisperse and 
polydisperse aerosols in the respiratory tracts of laboratory animals and human for 
particles ranging in size from ultrafine (1 nm) to coarse (100 µm). The parameters 
used by MPPD to calculate deposition comprise the type of airway morphometry, 
the particle properties and the exposure, as well as the breathing pattern. 
For the simulation of tracheobronchial clearance by the MPPD model, only the 
MCC values that significantly differed from the not treated value were used (time 
point at T20 and T40, Table 12) 
 
In the graphs (Figure 72) the simulation of the tracheobronchial clearance of a 
compound assuming standard parameters of particle diameter (3 µm) and rout of 
administration (oral rout) applying the different MCC calculated in vitro is 
represented. As it can be observed, the amount of mass cleared is significantly 
affected by the MCC.  
Interestingly, the tracheobronchial mass (TB mass) is significant affected starting 
from the T0, indicating that the MCC can modify the amount of compound that 













Table 12. MCC expressed as mm/sec calculated for each treatment. Correction factor = beads Speed 
(mm/sec) Not treated / 5.5  mm/sec. MCC= Beads Speed (mm/sec) treatment * correction 




















Not treated 0.39253 5.5 Not treated 0.09969 5.5
Budesonide  T0 0.42790 6.00 Fluticasone  T0 0.09088 5.01
Budesonide T10 0.39883 5.59 Fluticasone T10 0.08290 4.57
Budesonide T20 0.54076 7.58 Fluticasone T20 0.08279 4.57












Not treated 0.26381 5.5 Not treated 0.29431 5.5
Salbutamol  T0 0.31832 6.64 Theophylline  T0 0.29437 5.50
Salbutamol T10 0.23083 4.81 Theophylline T10 0.20174 3.77
Salbutamol T20 0.27307 5.69 Theophylline T20 0.24779 4.63
Salbutamol T40 0.35419 7.38 Theophylline T40 0.21277 3.98






Not treated 0.20450 5.5
Tiotropium  T0 0.16913 4.55
Tiotropium T10 0.17643 4.74
Tiotropium T20 0.25412 6.83






Figure 72. Graphical representation of tracheobronchial clearance (TB Mass Cleared) prediction 
of a generic compound (diameter 3 µM) via oral route on the basis of different MCC 
measured in vitro. A:  Budesonide 10 µM; B: Salbutamol 10 µM;. C: Tiotropium 10 µM; 



















































































































































6.1 Acute toxicity Assessment. 
The respiratory tract toxicity is a significant cause of failure of inhaled drug 
compound in clinical trials. Therefore, the early prediction of the respiratory 
toxicological effects potential is of interest for pharmaceutical industries.  
In this project, the commercial SmallAir™ tissue model (Epithelix) was 
characterized as possible in vitro model to evaluate different parameters of interest 
in drug discovery and development. 
Many studies describe application of in vitro model for the toxicity evaluation of 
nanomaterial (Loret et al., 2018; Mossman et al., 2007) or air pollution 
(Aufderheide et al., 2003; Upadhyay & Palmberg, 2018). Unfortunately, no toxic 
pharmaceutical compound was available to be tested in the model object of this 
study. Therefore a set of chemicals selected from the pre-validation study of a 
similar commercial respiratory in vitro model were assessed. 
In the acute toxicity test the model was able to identify the toxicity of a single 
treatment of the well-known toxic compound Dimethylamine. In a further 
experiment, where the tissues were treated with a single dose of chemical toxic 
substances (CdCl2 100 µM) and irritant and inflammatory stimuli such as LPS and 
TGF-β respectively, a significant decrease of viability confirmed the toxicity of 
CdCl2. The slight decrease observed for the tissues treated with TGF-β confirmed 
that the viability assessment by the Resazurin test allows to individuate toxic and 
irritant compound. These observations were confirmed also by the histological 
evaluation that showed a slight or moderate increase in apoptotic cells in LPS and 
TGF-β treated tissues and a severe tissue disorganization with necrotic areas in 
CdCl2 treated.  
The TEER measurement seems not to be a good parameter to assess tissue integrity 
for short time treatment (6 hours) since a decrease both for negative control and 
treated tissues was observed. While, for long time treatment the TEER 
measurement allows to assess the tissue damage after strong toxic compound. 
However, since TEER measurement is sensitive and many factors (such as 
temperature, medium formulation, cell culture period and shear stress) can affect 
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the TEER values, this parameters was considered not suitable as toxic end point 
(Srinivasan et al., 2015). 
When the 3D SmallAir™ and the A549 cell culture were compared in the 
evaluation of a dose range concentration of a set of toxic compounds,  the 
SmallAir™ seemed to be less sensitive than A549 showing higher EC75 values. 
This could be due to the different characteristics of the cell models. The SmallAir™ 
model is indeed a 3D tissue composed by different cell types in air-liquid interface 
maintaining physiological features such as cilia beating and mucus production that 
can protect the cells from the toxic effect, as already observed previously (Zavala, 
2016). The LDH release resulted not to be a significant parameter for predicting 
lung toxicity, since no dose related increase was observed. This could be due to the 
mechanism of action of toxic compounds tested. Compounds tested are chemical 
substances with a mechanism of action not well characterized.  These substances 
seemed to act mainly by corrosive mechanism with a consequent detachment of the 
cells that could be not resulting in an LDH release. Furthermore, the lack of LDH 
response could be due the presence of ciliated and mucus secreting cells and basal 
cells that likely could make this test system more resistant, as previous observed  
(Zavala, 2016).  
6.2 Transport Evaluation (Permeability)  
Permeability data obtained in SmallAir™ after liquid treatment showed to be 
comparable with permeability in Caco2. Differences observed between the two test 
systems seems to affect more low and medium permeability compounds. These 
observation should be due to the physiological differences between the two test 
systems. The Caco2 is the standard model used for the permeability study and it 
consists of immortalized cell line. The SmallAir™ is a pseudostratified epithelium 
derived from donor (different batch can show inter-batch variability) composed by 
different cell type expressing cilia and mucus production that can interfere with the 
permeability. Interestingly, the differences observed between the two models seems 
to be more evident for low and medium permeability compound. Furthermore, if 
different transporters are involved, the SmallAir™ values could be more 
representative of the in vivo situation. Therefore, Caco2 should be suggested as a 
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first model for preliminary screening and then the SmallAir™ can be used in 
following investigation as more physiological test systems. Indeed, if different 
transporter are present in lung tissue, the SmallAir™ could allow to obtain 
evaluation more representative of the in vivo situation. However, since the 
SmallAir™ model is still not well characterized for the permeability study of 
pharmaceutical compounds very few literature is published, therefore, more 
investigations are needed in order to identify and better characterize the membrane 
transporters expressed in this model. 
Unfortunately, the tests conducted with the CULTEX® RFS Compact as device to 
apply aerosol drug onto the tissues did not allow to reach conclusive results 
requiring further improvement in the instrument set up.  
Differently, the CULTEX® has been widely used for the assessment of traditional 
cigarette smoke, e-cigarette  (Grellet et al., 2013; Scheffler et al., 2015) and 
pollutant  effect on lung cell lines (Aufderheide & Mohr, 2000). In the early 2000s, 
electronic cigarettes were introduced as an aid for smoking cessation and 
replacement and in the last few years, the consumption has risen significantly. Even 
if, the regulation and control of e-cigarette liquids is not still standardized to ensure 
sufficient quality and safety for the user, the cytotoxic evaluation of e-cigarette 
aerosol is of great importance (Scheffler et al., 2015). In vitro e-cigarette aerosol 
testing are usually based on in vitro assays optimised for the assessment of cigarette 
smoke which is significantly different in terms of its chemical and physiological 
composition. Therefore, in vitro testing of e-cigarette aerosols still needs to be 
modified and adapted to the different characteristics of the aerosol produced. 
(Bishop et al., 2019). The aim of the test conducted and reported in this work, was 
to evaluate different concentrations of nicotine produced by two different devices 
and its permeability through lung tissues. Results obtained in the viability test, 
ensured that the tissue were viable immediately after the treatment, but nothing can 
be said regarding the cytotoxic effect of the e- smoke since only a short time 
treatment was applied. Interesting data for nicotine permeability were obtained, 




In the preliminary experiment with NGI cup modified for the treatment of 
compounds formulated as powder, promising results were obtained regarding the 
powder distribution. Further experiments should be conducted to optimize the 
instrument set-up in order to avoid tissues damages and assess the permeability of 
powders, thus mimicking as much as possible the in vivo process of dissolution and 
permeation through the lung epithelium.   
6.3 Inflammatory Mediators assessment 
TGF-β is one of the major mediators of ECM remodelling and epithelial-
mesenchymal transition (EMT) involved in  carcinogenesis and fibrosis (Kolosova 
et al., 2011). The pathway is complex and involves different signalling pathways 
including Smads, mitogen-activated protein kinase (MAPK), and 
phosphatidylinositol 3-kinase (PI3K). Differential roles for Smad2 and Smad3 have 
been demonstrated in different cell types suggesting that this pathway activation 
may depend on the particular cellular context. The involvement of Smad2 in the 
lungs fibrosis was reported by Willis et al. (Willis & Borok, 2007). They found that 
TGFβ1 could cause alveolar epithelial cells to undergo EMT both in vitro and in 
vivo by activating smad2. Furthermore, TGF-β1-induced Smad signalling in lung 
epithelial cells A549 was widely reported (Kunzmann et al., 2018; Tang et al., 
2019). Results obtained in this study confirmed that the signalling via Smad2 is 
present in the 3D SmallAir™ tissues. 
The bleomycin treatment of 3D SmallAir™ tissues did not reduce di viability, as 
already observed by previous author in a similar 3D lung tissues model 
(Willoughby, 2015). However the cytokines release did not correlate with what 
observed by Willoghby and colleagues. They showed that bleomycin induces 
expression of CYP1A1, Bcl2, TNFa, IL-1a, IL-6, and IL-8 in EpiAirway 3D model 
confirming well known in vivo responses in humans and mice, as well as known 
responses of human cells in culture to bleomycin exposure (Cavarra et al., 2004; 
Willoughby, 2015). These difference in the results could be explain with the fact 
that in the present study the cytokine release in the medium and not the gene 
expression, was assessed. Therefore, low concentration in the medium could be not 
determined with the same sensibility as the gene expression analysis. While IL-8 
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and GRO levels showed to be out of range (for these parameters a sample dilutions 
should be recommended for further assay). Also, the LDH and ROS release 
measurement did not allow to assess the effect of bleomycin treatment on the 
SmallAir™.   Since all evaluation were not consistent, some concerns about the 
bleomycin functionality have arisen. However, only one experiment was 
conducted, therefore further test are suggested to be performed in order to better 
characterize the cytokine release in the SmallAir™ model.  
6.4 Muco-ciliary clearance 
Results obtained in the evaluation of the effect Forskolin and CFTR confirmed the 
agonist and inhibitor effect on MCC respectively. Forskolin is a member of the 
diterpene family and it activates the Cystic fibrosis transmembrane conductance 
regulator (CFTR) chloride channel by raising the amount of intracellular cyclic 
AMP, leading to fluid secretion, while CFTRInh-172, an inhibitors of CFTR 
chloride channel, is used as tools to investigate the role and function of CFTR 
conductance in cystic fibrosis research. (Melis et al., 2014). Results obtained in 
SmallAir™ after FRSK and CFTR treatment correlated with observation by Joo 
N.S et al.. They reported in an ex vivo ferret trachea model that CFTR inhibitors 
modestly depressed MCCV stimulated by [cAMP]i –elevating agents, but not basal 
MCCV nor that stimulated by [Ca2+]–elevating agents (Joo et al., 2016). The 
Carbachol a synthetic choline that acts a nicotinic acetylcholine receptor agonist, 
was used to induce [Ca2+]. However, conflicting results obtained after Carbachol 
treatment, did not allowed to confirm  its effect on MCC (Joo et al., 2016).  
The increase in MCC observed after Budesonide and Salbutamol confirmed the 
results already reported (Houtmeyers et al., 1999). Salbutamol is an adrenergic 
agents acting as bronchodilator. In addition to their relaxing effect on the bronchial 
smooth muscle, adrenergic agents are also reported to have an effect on MCC. In 
vivo data, showed that the single inhalation of adrenergic agonist is able to increase 
MCC significantly (Houtmeyers et al., 1999). 
Budesonide and Fluticasone propionate are corticosteroids used in the treatment of 
chronic obstructive lung disease and asthma. Regarding the influence of 
corticosteroids on MCC, corticosteroids showed to increase the cilia beating 
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frequency significantly in isolated bronchial preparations in rats (Houtmeyers et al., 
1999). Fluticasone results obtained in this study did not confirm this observation, 
therefore further experiments are needed to better elucidate its effect on SmallAir™ 
tissues.  
Regarding the Tiotropium bromide effect, discordant results have been reported. 
Inhaled tiotropium bromide has been shown to improve lung function and reduce 
cough but muco-ciliary clearance was not improved in patients with COPD (Hasani 
et al., 2003). Other studies showed that tiotropium decreases symptoms in patients 
with COPD after tiotropium treatment. This effect may be derived from the 
inhibition of airway mucus hypersecretion and the improvement of airway 
mucociliary clearance (Tagaya et al., 2016).  
Results obtained after Fluticasone treatment in SmallAir™ tissues confirmed the 
no effect on MCC as observed in vivo  (Gizurarson, 2015). 
Discordant results was also observed in the Theophylline treatment. The 
methylxanthines, such as the Theophylline, are demonstrated to have a stimulative 
effect on lung MCC (Houtmeyers et al., 1999), while a decrease in the MCC was 
observed in the present study. The mechanism responsible for the observed 
improvement in MCC still remains a matter of debate.  Administration of 
methylxanthines might increase the secretion of mucus, increasing the CBF as well 
as stimulate the secretion of fluid into the airway lumen, all factors involved in the 
final outcome of MCC. This particular mechanism of action could be not properly 
evaluated by the study design applied in this study, due to the washing step and time 
of exposure (Houtmeyers et al., 1999). 
 
In conclusion, the in vitro SmallAir™ model, showed to be a promising model to 
assess the MCC in vitro after treatment with compound acting on ATP release and 
CFTR172inh. Further tests should be conducted to optimize the study design and 
confirm data obtained following inhaled compound treatment. For example, also 
the cilia beating frequency should be directly assessed in addition to the assessment 
of the MCC. Indeed, the suspension with beads applied as tracker, may be not able 




6.5 In silico Prediction 
In vitro and in vivo approaches are still costly and time-consuming. In experimental 
approaches comparison, computational methods have shown great advantages since 
they are fast, cheap, accurate, and most importantly they could be done before a 
compound is synthesized (Yang et al., 2018) 
Several different in silico or non-testing approaches can help to predict the toxicity 
of substances after inhalation. These approaches are usually applied for chemicals 
and are considered to address further assessment such as hazard identification, 
quantitative risk assessment and national exposure standard setting (Clippinger, 
Allen, Behrsing, et al., 2018). 
These approaches, to varying degrees, are based on the principle that similar 
substances are expected to exhibit similar biological activities.  
Many in silico models are available and can be used individually or in an integrated 
fashion. Computational models developed for drug safety assessment can be 
generally divided into three categories: computational models based on SAR, 
Quantitative Structure-Activity Relationship modeling (QSAR), read-across 
extrapolations from measured data on analogous chemicals (Yang et al., 2018). 
The availability of non-testing approaches to predict toxicity after acute inhalation 
exposures is limited and generally developed for chemical exposure. 
The use of integrated approaches that combine existing data with in vitro and/or 
computational approaches to generate new data is fundamental to achieve global 
regulatory acceptance for non-animal testing approaches. Currently the biggest 
challenges are represented by the absence of centralized database of existing 
inhalation toxicity data and the identification and optimization of appropriate in 
silico models. 
These topics require a global effort that were deeply discussed in 2016 at 
“Alternative Approaches for Acute Inhalation Toxicity Testing to Address Global 
Regulatory and Non-Regulatory Data Requirements”. Currently such models and 
databases are not yet available and this makes the use of animal models inevitable. 
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Poor pharmacokinetics along with toxicity of inhaled drug are important causes of 
costly late-stage failures in drug development (van de Waterbeemd & Gifford, 
2003), therefore an early evaluation of these aspects has become important.  
Pharmacokinetic studies support the studies of preclinical toxicology in animals 
(toxicokinetics) and allow to evaluate the correct use of drugs in therapy (choice of 
the best route of administration, choice of the best dose regimen, dose 
individualization, etc.) (Urso et al., 2002).  
Compared with other routes of administration, a drug can be directly delivered to 
the target organ by the inhalation, conferring high local drug concentrations and, on 
the basis of its specific physico-chemical features, a low systemic drug 
concentrations. Therefore, drug inhalation is typically associated with high 
pulmonary efficacy and minimal systemic side effects.  
However the lung is an organ with a complex structure and multiple pulmonary-
specific properties that can affect the pharmacokinetic (Borghardt et al., 2018).  
Furthermore, local lung concentrations together with the systemic drug 
concentrations must be considered to assess the systemic safety profile of an inhaled 
drug. The systemic concentrations depend on a number of factors, including 
gastrointestinal absorption of the swallowed fraction of the drug, the rate and extent 
of absorption via pulmonary PK processes, and systemic disposition properties, 
such as distribution and elimination. Therefore characterizing the PK of inhaled 
drugs is highly complex because both the pulmonary and systemic PK have to be 
simultaneously evaluated. (Borghardt et al., 2018) 
The systemic PK profiles of inhaled drugs in humans are still not fully interpretable 
and predictable in relation to the drug's molecular properties, inhaled aerosol 
delivery, and regional deposition, and various lung disposition mechanisms (such 
as muco-ciliary clearance, degradation, tissue binding/sequestration, and 
phagocytosis) (Raut et al., 2020). Several in vivo methods are applied to evaluate 
the drug deposition in the lung. Monitoring the pulmonary delivery is important to 
evaluate new delivery methods, new therapeutic drug formulations and for patients 
with impaired lung function that may require a confirmation of compound delivery 
(Tay et al., 2018). In vivo methods are technically demanding, require specific 
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tracers and are expensive. Therefore there is an arising interest for computational 
models (Fröhlich et al., 2016) 
In recent years, several in silico methods have been developed in order to design 
specific molecule and predict their absorption, distribution, metabolism and 
excretion proprieties.  Several software, can simulate the pharmacokinetic of drugs 
given by oral route using an integration of in silico, in vitro and in vivo data.  
However, compared to oral application, prediction of plasma profiles of inhaled 
drugs is rarely reported (Fröhlich et al., 2016). 
A PBPK (physiologically based pharmacokinetic) model is a mechanistic approach 
for predicting the pharmacokinetics of drugs with various degrees of accuracy based 
on pulmonary PK (e.g., dissolution, absorption) and systemic PK (e.g., distribution, 
excretion). The PBPK model incorporates anatomical and physiological aspects 
(e.g., organ perfusion rate, absorption surface area, etc.) and physico-chemical 
characteristics of the drug. Since the PBPK models is developed based on these 
predefined parameters it also called “bottom-up” approach, differently from “top-
down” that predicts PK parameters from clinical data (Borghardt et al., 2015). 
In preliminary evaluation, Salbutamol and Budesonide permeability results 
obtained in SmallAir™ were used to evaluate the potential integration of these in 
vitro data with PBPK predictions. The PBPK predictions provided very reasonable 
agreement between observed and simulated plasma concentration-time profiles. In 
particular, for the absorption process, values obtained in SmallAir™ seems to fit 
well the literature in vivo data, even if the access to reliable in vivo data for the 
validation of in silico models is still an issue (L. Pomari 2019).   
The results obtained in the clearance simulation with MPPD, showed that the 
deposition and the time of elimination of an inhaled compound can be significantly 
affected by the variation on MCC that the compound itself can cause. Using a value 
of MCC measured in in vitro preliminary assessment can be really useful to evaluate 
the deposition of particles, which could affect the pharmacokinetic profile of the 




The respiratory system is an important site for local and systemic drug delivery. 
Despite the popularity of inhalation as a drug delivery route, assessing the fate of 
inhaled compounds is difficult because of the complex nature of the lung. 
Preclinical testing involves the use of primarily animal models to evaluate the 
deposition of a new drug in the appropriate tract of the respiratory system and to 
assess the correct therapeutic activity; and possible local and systemic toxicity. 
This information are useful to improve formulations and delivery devices, or, if 
necessary, to decide to discard the drug prior to first-in-man studies. 
However, major losses of new drug candidates can occur in first-in-man studies, for 
a variety of reasons such as failure in the deposition at the correct site; presence of 
effects in humans not observed in animals.  
There is an urgent need to develop in vitro human based models, in order to better 
assess the possible toxicity effect and to evaluate the permeability of new inhaled 
medicines. 
Indeed, a better in vitro characterization of new molecules in the early stage of the 
drug development should help in the selection of the best candidate for pre-clinical 
and clinical study, allowing to reduce in vivo study and reduce the risk of failure in 
first-in-man studies. 
The in vitro studies conducted until now need to be carefully considered since at 
the moment a known reliable and validated test system has not been identified yet. 
However, this thesis wanted to be a first step in the direction of the development of 
an ethical and practical test system to improve the new inhaled drug selection and 
reduce the amount of animal tests conducted.  
In this project, the 3D SmallAir™ model was characterized as possible more human 
relevant in vitro model to be used in the inhaled drug discovery sector. Different 
aspect has been investigated. 
In particular, aspect such as the toxicity, the permeability and the effect on MCC 
were assessed. Furthermore, some in vitro data obtained have been used as input 
data for in silico evaluation, in order evaluate the reliability of a possible integrated 
approach to better characterize new molecules. 
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Regarding the in vitro toxicity assessment on the respiratory system very few 
literature was found for pharmaceutical compound. In this project I focused on the 
evaluation of well-known respiratory chemicals toxicant and irritant compounds on 
both a cell model and SmallAir™ model. TEER, LDH and viability test have been 
considered as end point. TEER and LDH showed not to be feasible parameters for 
predicting lung toxicity in the test system considered, while data obtained by the 
Resazurin viability test confirmed its reliability in the toxicity assessment. The 
viability results were also confirmed by the histology analysis. Furthemore, in the 
toxicity tests, the SmallAir™ model seemed to be less sensitive than A549 showing 
higher EC75 values. This property can be explained by the 3D structure 
physiological features such as cilia beating and mucus production that can protect 
the cells from the toxic effect. 
For the permeability study, I focused on well-known inhalation compounds with 
very different permeability values (for example, low for Salbutamol and high for 
Budesonide) which resulted to be comparable in the two test systems considered. 
The most evident difference was observed with medium permeable compounds 
such as Digoxin. Results obtained in this study, indicate that the SmallAir™ model 
should express different efflux pumps on their surface compared to the standard 
Caco2 cell model. The exact type of transporters and their distribution and activity 
in the SmallAir™ test system have not been yet characterized, therefore tests 
conducted so far can only inform whether a compound is actively transported or 
not.  
Regarding the different methods of compound application explored, more 
experiment are needed to optimize the instrument set up for the aerosol and powder 
treatment. If successful, these experiments should give results that, used in in silico 
predictions, can reflect the in vivo data, since they will take into consideration also 
the dissolution profile in the lung, which is one of the limits of the current 
predictions.  
 
For the evaluation of the SmallAir™ model as a possible in vitro lung model for 
the assessment of inflammatory mediators, tissues were treated with TGF-β and 
Bleomycin. Results obtained with the treatment TGF-β confirm the activation of 
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Smad2 pathway. Unfortunately, results obtained in the measurement of cytokines 
LDH and ROS release after bleomycin treatment were not consistent with the 
literature. However only one experiment was conducted, therefore further 
experiments are suggested in order to confirm results obtained.  
 
The SmallAir™ model was also evaluated as in vitro model for the assessment of 
the MCC. Results obtained in this project, showed that the SmallAir™ can be a 
promising model to assess the MCC in vitro after treatment with compound acting 
on ATP release and CFTR172inh, while further tests should be conducted to 
optimize the study design for the evaluation of the effect of different compound on 
cilia beating and MCC. 
 
Finally, some integrations of in vitro data with in silico method were considered in 
order to establish an integrated strategy in the inhaled drug development. 
Unfortunately, so far no specific data base for the respiratory toxicity are 
commercially available, therefore in this project no integration of in vitro toxicity 
data with in silico approach was feasible.  
MCC data were also used for the clearance simulation using the MPPD model. 
Result obtained showed that the deposition and the time of elimination of an inhaled 
compound can be significantly affected by the variation on MCC that the compound 
itself can cause. This indicates that such an assessment performed at the early stage 
of development can be useful in the evaluation of the pharmacokinetic profile of 
the compound of interest. 
I am aware that tests performed so far are only a first step in the characterization of 
an in vitro lung model. However, overall these preliminary results can be 
considered promising. More compounds and conditions must be investigated, in 
order to validate a human relevant in vitro lung model to be applied in many fields 
of analysis, from permeability and transporters, to toxicity, formulation 
development, in vitro pharmacology etc. The organoid 3D tissues may represent a 
promising developing area to fill the gaps both in the drug discovery and the drug 
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